NCT04472572
|
Expanded Access to Convalescent Plasma for Treatment of COVID-19 |
Available |
|
Jan/01/1970 |
Jan/01/1970 |
- Alternative id - Pro2020-0663
- Interventions - Biological: Convalescent Plasma
- Study type - Expanded Access:Treatment IND/Protocol
- Study results - No Results Available
- Locations - Hackensack University Medical Center, Hackensack, New Jersey, United States
- Study designs -
- Enrollment -
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures -
|
NCT04359810
|
Plasma Therapy of COVID-19 in Severely Ill Patients |
Completed |
Phase 2 |
Apr/21/2020 |
Dec/30/2020 |
- Alternative id - AAAS9924
- Interventions - Biological: Convalescent Plasma (anti-SARS-CoV-2 plasma)|Biological: Non-convalescent Plasma (control plasma)
- Study type - Interventional
- Study results - No Results Available
- Locations - Columbia University Irving Medical Center/NYP, New York, New York, United States|Hospital Federal dos Servidores do Estado, Rio De Janeiro, Brazil|Hospital Geral de Nova Iguaçu, Rio De Janeiro, Brazil|Instituto Nacional de Infectologia Evandro Chagas, Rio De Janeiro, Brazil
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment
- Enrollment - 223
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Day 28 severity outcome|Proportion of SARS-CoV-2 PCR Positivity|Levels of SARS-CoV-2 RNA|Duration of Need for Supplemental Oxygen|Duration of Hospitalization|In-hospital and 28-day mortality|Time-to-clinical improvement in-hospital|Host genetic differences at day 0|Host transcriptomic differences at days 0,7,14
|
NCT04408209
|
Convalescent Plasma for the Treatment of Patients With Severe COVID-19 Infection |
Recruiting |
Not Applicable |
Apr/23/2020 |
Sep/15/2021 |
- Alternative id - 245-14-4-20
- Interventions - Procedure: Convalescent Plasma
- Study type - Interventional
- Study results - No Results Available
- Locations - "Evangelismos" General Hospital, Athens, Attiki, Greece|"Agios Savas" Oncology Hospital, Athens, Attiki, Greece|"Alexandra" General Hospital, Athens, Attiki, Greece|"Sotiria" General Hospital, Athens, Attiki, Greece|Attikon" University General Hospital, Athens, Chaidari, Greece|University General Hospital of Patras, Patra, Rio, Greece
- Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 60
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Survival|Clinical improvement ie percentage of patients not fulfilling the criteria for severe disease
|
NCT04480632
|
Therapeutic Plasmapheresis in Critically Ill Adult Patients With COVID-19 Confirmed Diagnosis |
Not yet recruiting |
Phase 2 |
Aug/01/2020 |
Aug/01/2022 |
- Alternative id - CEI-2020-01200
- Interventions - Biological: Convalescent plasma
- Study type - Interventional
- Study results - No Results Available
- Locations - Hospital Internacional de Colombia, Piedecuesta, Santander, Colombia
- Study designs - Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 44
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - In-hospital mortality|Incidence of renal replacement therapy|Incidece of adverse events
|
NCT04769245
|
The Effectiveness of ACB-IP 1.0 Convalescent Plasma in COVID-19 Infection |
Recruiting |
|
Feb/18/2021 |
Jun/01/2021 |
- Alternative id - Acibadem Healthcare Group
- Interventions -
- Study type - Observational
- Study results - No Results Available
- Locations - Acıbadem Labcell Cellular Therapy Laboratories, Istanbul, Turkey|Acibadem Altunizade Hospital, Istanbul, Turkey
- Study designs - Observational Model: Case-Only|Time Perspective: Retrospective
- Enrollment - 40
- Age - 18 Years to 75 Years (Adult, Older Adult)
- Outcome measures - Mortality Rate|Length of Hospitalization|Side Effects
|
NCT05157165
|
Convalescent Plasma in Hospitalized COVID-19 Patients |
Available |
|
Jan/01/1970 |
Jan/01/1970 |
- Alternative id - 00001
- Interventions - Biological: Convalescent plasma
- Study type - Expanded Access
- Study results - No Results Available
- Locations -
- Study designs -
- Enrollment -
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures -
|
NCT04348656
|
CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1) |
Terminated |
Phase 3 |
Mar/14/2020 |
Jun/16/2021 |
- Alternative id - CONCOR-1
- Interventions - Biological: Convalescent plasma
- Study type - Interventional
- Study results - Has Results
- Locations - Brooklyn Hospital, Brooklyn, New York, United States|Lower Manhattan Hospital, New York, New York, United States|Weill Cornell Medical Center, New York, New York, United States|Hospital Universitário Antônio Pedro (HUAP), Niterói, Brazil|Hemario, Rio De Janeiro, Brazil|Peter Lougheed Center, Calgary, Alberta, Canada|Foothills Medical Centre, Calgary, Alberta, Canada|Rockyview General Hospital, Calgary, Alberta, Canada|University of Alberta - Royal Alexandra Hospital, Edmonton, Alberta, Canada|University of Alberta Hospital, Edmonton, Alberta, Canada|Sturgeon Community Hospital, St. Albert, Alberta, Canada|Fraser Health Authority - Abbotsford Regional Hospital and Cancer Centre, Abbotsford, British Columbia, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|St. Paul's Hospital, Vancouver, British Columbia, Canada|Royal Jubilee Hospital, Victoria, British Columbia, Canada|Victoria General Hospital, Victoria, British Columbia, Canada|St. Boniface General Hospital, Winnipeg, Manitoba, Canada|Health Sciences Centre Winnipeg, Winnipeg, Manitoba, Canada|Grace General Hospital, Winnipeg, Manitoba, Canada|Vitalité Health Network - Acadie-Bathurst, Bathurst, New Brunswick, Canada|Vitalité Health Network - Restigouche, Campbellton, New Brunswick, Canada|Vitalité Health Network- Northwest, Edmundston, New Brunswick, Canada|Dr. Georges-L.-Dumont University Hospital Centre, Moncton, New Brunswick, Canada|Lakeridge Health Ajax Pickering, Ajax, Ontario, Canada|Hamilton General Hospital, Hamilton, Ontario, Canada|Juravinski Hospital, Hamilton, Ontario, Canada|St. Joseph's Healthcare, Hamilton, Ontario, Canada|Grand River Hospital, Kitchener, Ontario, Canada|St. Mary's Hospital, Kitchener, Ontario, Canada|London Health Sciences Centre - University Hospital, London, Ontario, Canada|Victoria Hospital, London, Ontario, Canada|Markham Stouffville Hospital, Markham, Ontario, Canada|Trillium Health Partners - Mississauga Hospital, Mississauga, Ontario, Canada|Trillium Health Partners - Credit Valley, Mississauga, Ontario, Canada|North York General Hospital, North York, Ontario, Canada|Lakeridge Health Oshawa, Oshawa, Ontario, Canada|Ottawa Hospital - General Campus, Ottawa, Ontario, Canada|Ottawa Hospital - Civic Campus, Ottawa, Ontario, Canada|Queensway Carleton Hospital, Ottawa, Ontario, Canada|Bluewater Health, Sarnia, Ontario, Canada|Scarborough Health Network, Centenary Hospital, Scarborough, Ontario, Canada|Scarborough Health Network, General Hospital, Scarborough, Ontario, Canada|Scarborough Health Network, Birchmount Hospital, Scarborough, Ontario, Canada|Niagara Health System - St. Catherines, St. Catherines, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Unity Health St. Michael's Hospital, Toronto, Ontario, Canada|Sinai Health System, Toronto, Ontario, Canada|Toronto General Hospital, Toronto, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|Unity Health, St. Joseph's Health Care Centre, Toronto, Ontario, Canada|Windsor Regional Hospital - Metropolitan Campus, Windsor, Ontario, Canada|Windsor Regional Hospital - Ouellette Campus, Windsor, Ontario, Canada|L'Hopital Chicoutimi, Chicoutimi, Quebec, Canada|Hôpital de la Cité-de-la-Santé, Laval, Quebec, Canada|Hôpital Charles-Le Moyne, Longueuil, Quebec, Canada|Hotel Dieu Hospital of Lévis, Lévis, Quebec, Canada|Hôpital Maisonneuve-Rosemont, Montréal, Quebec, Canada|Centre hospitalier de l'Université de Montréal, Montréal, Quebec, Canada|Montréal General Hospital, Montréal, Quebec, Canada|Centre hospitalier universitaire Sainte-Justine, Montréal, Quebec, Canada|Jewish General Hospital, Montréal, Quebec, Canada|McGill University Health Centre, Montréal, Quebec, Canada|Hôpital du Sacré-Coeur de Montreal, Montréal, Quebec, Canada|Centre Hospitalier Universitaire (CHU) de Québec - Université Laval, Quebec City, Quebec, Canada|Institut Universitaire de cardiologie et pneumologie de Québec, Quebec City, Quebec, Canada|Centre hospitalier régional de St-Jérôme, Saint-Jérôme, Quebec, Canada|Centre Hospitalier Universitaire de Sherbrooke (CHUS) - Hôpital Hôtel-Dieu, Sherbrooke, Quebec, Canada|Centre Hospitalier Universitaire de Sherbrooke (CHUS) - Hôpital Fleurimont, Sherbrooke, Quebec, Canada|Centre hospitalier affilié universitaire régional de Trois-Rivières, Trois-Rivières, Quebec, Canada|Regina General Hospital, Regina, Saskatchewan, Canada|Pasqua Hospital, Regina, Saskatchewan, Canada|St. Paul's Hospital, Saskatoon, Saskatchewan, Canada|Royal University Hospital, Saskatoon, Saskatchewan, Canada
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 940
- Age - 16 Years and older (Child, Adult, Older Adult)
- Outcome measures - Number of Participants Who Were Intubated or Died|Time to Intubation or In-hospital Death|Ventilator-free Days by Day 30|Death by Day 30|Length of Stay in Intensive Care Unit (ICU)|Need for Renal Replacement Therapy|Need for Extracorporeal Membrane Oxygenation (ECMO)|Development of Myocarditis|In-hospital Death|Time to In-hospital Death|Length of Stay in Hospital|Number of Participants With Grade 3 and 4 Serious Adverse Events|Number of Participants With CCP Transfusion-associated Adverse Events (AE)|Number of Participants With Grade 3, 4, or 5 Serious Adverse Events|Patient Reported Outcome Using Change in EQ-5D-5L Score|Patient Reported Outcome- Quality-adjusted Life Days|Cost of Intervention and Hospital Stay
|
NCT04542967
|
Study on the Safety and Efficacy of Convalescent Plasma in Patients With Severe COVID-19 Disease |
Completed |
Phase 2 |
Jun/23/2020 |
Sep/30/2020 |
- Alternative id - 047/2020
- Interventions - Biological: Biological
- Study type - Interventional
- Study results - No Results Available
- Locations - Hospital Central Militar, Mexico City, Mexico
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
- Enrollment - 150
- Age - 18 Years to 90 Years (Adult, Older Adult)
- Outcome measures - Disease progression|Side effects|Mortality|Respiratory improvement|Clinical improvement|Acute adverse events (AAE)
|
NCT04345991
|
Efficacy of Convalescent Plasma to Treat COVID-19 Patients, a Nested Trial in the CORIMUNO-19 Cohort |
Completed |
Phase 2 |
Apr/15/2020 |
May/28/2021 |
- Alternative id - APHP200375-10|2020-001246-18
- Interventions - Drug: Transfusion of COVID-19 convalescent plasma
- Study type - Interventional
- Study results - No Results Available
- Locations - SMIT, Saint Antoine hospital, Paris, France
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 120
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Survival without needs of ventilator utilization or use of immunomodulatory drugs (other than steroids)|WHO progression scale ≥6|Severe adverse events|WHO progression scale|Overall survival|Time from randomization to discharge|Time to oxygen supply independency|Survival without needs of ventilator utilization|Survival without use of immunomodulatory drugs
|
NCT04649879
|
Convalescent Plasma for Treatment of COVID-19 |
Completed |
Phase 2|Phase 3 |
Dec/03/2020 |
Jan/26/2022 |
- Alternative id - CP3
- Interventions - Biological: SARS-CoV-2 convalescent plasma|Other: Standard of care
- Study type - Interventional
- Study results - No Results Available
- Locations - Department of Infectious Disease, Falu Hospital, Falun, Dalarn, Sweden|Department of Geriatrics, Karolinska University Hospital, Stockholm, Sweden|Danderyd Hospital, Stockholm, Sweden
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 59
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - COVID-19 related mortality within 28 days|COVID-19 related mortality within 60 days|Requirement of invasive ventilation or Pao2/FiO2 ≤ 70 for ≥ 12 hours in the case of patients not eligible for intensive care|Adverse events|Dose of plasma needed to clear viremia|Time to clearance of viremia
|
NCT04363034
|
Arkansas Expanded Access COVID-19 Convalescent Plasma Treatment Program |
Temporarily not available |
|
Jan/01/1970 |
Jan/01/1970 |
- Alternative id - 260944
- Interventions - Biological: Convalescent Plasma
- Study type - Expanded Access:Intermediate-size Population
- Study results - No Results Available
- Locations -
- Study designs -
- Enrollment -
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures -
|
NCT04345679
|
Anti COVID-19 Convalescent Plasma Therapy |
Recruiting |
Early Phase 1 |
Apr/14/2020 |
Sep/01/2021 |
- Alternative id - AntiCOVID19ORT
- Interventions - Biological: anti-SARS-CoV-2 convalescent plasma
- Study type - Interventional
- Study results - No Results Available
- Locations - Semmelweis University's Department of Pulmonology, Budapest, Hungary
- Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 20
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Changing of viral load of SARS-CoV2|Changes in immunglobulin G COVID-19 antibody titer|Changes at the cytokine pattern|Intensive Care Unit Admission|Length of hospital stay|Duration of mechanical ventilation|Clinical Status|Mortality
|
NCT04408040
|
Use of Convalescent Plasma for COVID-19 |
Terminated |
Phase 2 |
Jul/14/2020 |
Sep/14/2021 |
- Alternative id - NSH 1281
- Interventions - Biological: Convalescent Plasma
- Study type - Interventional
- Study results - No Results Available
- Locations - Northside Hospital, Atlanta, Georgia, United States
- Study designs - Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 7
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Arms 1 & 2: number of critical and severe COVID-19 infected patients who are transfused with convalescent plasma result in lower death rates than the reported fatality rate|Arms 1 & 2: number of critical and severe COVID-19 infected patients who survive the infection|Arm 3: number of high risk COVID-19 infected patients who are transfused with convalescent plasma result in lower incidence of progression to severe or critical disease than the reported case rate|Arm 4: number of health care providers who are at risk to exposure to COVID-19 who are transfused with convalescent plasma result in lower incidence of developing COVID-19 infection than the reported case rate
|
NCT04388410
|
Safety and Efficacy of Convalescent Plasma Transfusion for Patients With COVID-19 |
Recruiting |
Phase 2|Phase 3 |
Aug/25/2020 |
Dec/31/2020 |
- Alternative id - 3380
- Interventions - Biological: convalescent plasma
- Study type - Interventional
- Study results - No Results Available
- Locations - Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Tlalpan, Mexico
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
- Enrollment - 410
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Severity and death|Adverse events that require study treatment interruption|Time to clinical improvement|Antibodies against SARS-CoV-2|Disease progression 1|Disease progression 2|Time on mechanical ventilation|Number of days with fever|Adverse events attributed to the study intervention
|
NCT04644198
|
Convalescent Plasma Transfusion in Severe COVID-19 Patients in Jamaica |
Recruiting |
Phase 2 |
Jun/01/2021 |
Dec/01/2021 |
- Alternative id - ECP/195,19/20
- Interventions - Biological: Convalescent Plasma Infusion
- Study type - Interventional
- Study results - No Results Available
- Locations - University of the West Indies, Kingston, Jamaica
- Study designs - Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 30
- Age - 18 Years to 65 Years (Adult, Older Adult)
- Outcome measures - Mortality|Viral load|Antibody titre for Immunoglobulin (IgG) anti-SARS-CoV-2 antibody|Antibody titre for Immunoglobulin A (IgA) anti-SARS-CoV-2 antibody|Procalcitonin titres|Interleukin 6 (IL-6)|D-dimer|C-reactive protein|Ferritin|Length of ICU admission|Days to recovery
|
NCT04555109
|
Convalescent Plasma for COVID-19 Research Donor Study |
Active, not recruiting |
|
Jun/30/2020 |
Oct/31/2022 |
- Alternative id - 1000070462
- Interventions -
- Study type - Observational
- Study results - No Results Available
- Locations - The Hospital for Sick Children, Toronto, Ontario, Canada
- Study designs - Observational Model: Cohort|Time Perspective: Prospective
- Enrollment - 1000
- Age - 17 Years to 85 Years (Child, Adult, Older Adult)
- Outcome measures - Seroprevalence and duration of protective immunity
|
NCT04528368
|
Convalescent Plasma for Treating Patients With COVID-19 Pneumonia Without Indication of Ventilatory Support |
Recruiting |
Phase 2 |
Dec/11/2020 |
Jan/30/2022 |
- Alternative id - 34651120.8.0000.5249
- Interventions - Biological: Convalescent plasma
- Study type - Interventional
- Study results - No Results Available
- Locations - D'Or Institute for Research and Education, Rio de Janeiro, Brazil
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 60
- Age - Child, Adult, Older Adult
- Outcome measures - Area under the curve of SARS-COV-2 viral load obtained from nasopharyngeal and /or oropharyngeal swabs.|Assessment of clinical improvement using an Ordinal Severity Scale|Evaluate oxygen saturation|Evaluate oxygen supplementation|Assess respiratory rate|Evaluate the PaO2 / FiO2 ratio (for patients on mechanical mechanisms)|Length of hospital stay|Length of stay in intensive care|Assess the rate of orotracheal intubation|Change in the profile of cytokines/chemokines in both groups|Presence of antibodies against SARS-CoV-2 in serum after convalescent plasma administration|Death rate|Rate of transfusion reactions to convalescent plasma infusion
|
NCT02735707
|
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia |
Recruiting |
Phase 3 |
Apr/11/2016 |
Dec/01/2025 |
- Alternative id - U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584
- Interventions - Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Standard course macrolide|Drug: Extended course macrolide|Other: No systemic corticosteroid|Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Fixed-duration higher dose Hydrocortisone|Other: No antiviral agent for influenza|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Other: No antiviral agent for COVID-19|Drug: Lopinavir / Ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Ivermectin|Other: No immune modulation for COVID-19|Drug: Interferon beta-1a|Drug: Anakinra|Drug: Tocilizumab|Drug: Sarilumab|Drug: Local standard venous thromboprophylaxis|Drug: Therapeutic anticoagulation|Drug: Conventional low dose thromboprophylaxis|Drug: Intermediate dose thromboprophylaxis|Drug: Continuation of therapeutic dose anticoagulation|Other: No immunoglobulin|Biological: Convalescent plasma|Biological: Delayed administration of convalescent plasma|Other: No vitamin C|Drug: Vitamin C|Other: No antiplatelet|Drug: Aspirin|Drug: P2Y12 inhibitor|Other: No simvastatin|Drug: Simvastatin|Other: Placebo|Drug: Eritoran|Drug: Apremilast|Procedure: Clinician-preferred mechanical ventilation strategy|Procedure: Protocolised mechanical ventilation strategy|Other: No renin-angiotensin system inhibitor|Drug: Angiotensin converting enzyme inhibitor|Drug: Angiotensin Receptor Blockers|Drug: ARB + DMX-200|Other: No cysteamine|Drug: Cysteamine
- Study type - Interventional
- Study results - No Results Available
- Locations - University of Florida, Jacksonville, Florida, United States|Augusta University, Augusta, Georgia, United States|University of Illinois Health, Chicago, Illinois, United States|Tulane Medical Center, New Orleans, Louisiana, United States|University of Michigan, Ann Arbor, Michigan, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|University of Pittsburgh Medical Centre, Pittsburgh, Pennsylvania, United States|Brown University - Rhode Island Hospital, Providence, Rhode Island, United States|Canberra Hospital, Canberra, Australian Capital Territory, Australia|Bankstown-Lidcombe Hospital, Bankstown, New South Wales, Australia|Blacktown Hospital, Blacktown, New South Wales, Australia|Campbelltown Hospital, Campbelltown, New South Wales, Australia|Sutherland Hospital, Caringbah, New South Wales, Australia|Concord Hospital, Concord, New South Wales, Australia|Dubbo Base Hospital, Dubbo, New South Wales, Australia|Northern Beaches Hospital, Frenchs Forest, New South Wales, Australia|Nepean Hospital, Kingswood, New South Wales, Australia|St. George Hospital, Kogarah, New South Wales, Australia|Liverpool Hospital, Liverpool, New South Wales, Australia|John Hunter Hospital, Newcastle, New South Wales, Australia|Orange Health Service, Orange, New South Wales, Australia|St Vincent's Hospital Sydney, Sydney, New South Wales, Australia|Prince of Wales Hospital, Sydney, New South Wales, Australia|Royal Prince Alfred Hospital, Sydney, New South Wales, Australia|Royal North Shore Hospital, Sydney, New South Wales, Australia|Wollongong Hospital, Sydney, New South Wales, Australia|Wagga Wagga Base Hospital, Wagga Wagga, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Royal Darwin Hospital,, Darwin, Northern Territory, Australia|Sunshine Coast University Hospital, Birtinya, Queensland, Australia|The Prince Charles Hospital, Brisbane, Queensland, Australia|Mater Hospital Brisbane, Brisbane, Queensland, Australia|Princess Alexandra Hospital, Brisbane, Queensland, Australia|Caboolture Hospital, Caboolture, Queensland, Australia|Queen Elizabeth II Jubilee Hospital, Coopers Plains, Queensland, Australia|Logan Hospital, Logan, Queensland, Australia|Redcliffe Hospital, Redcliffe, Queensland, Australia|Rockhampton Hospital, Rockhampton, Queensland, Australia|Gold Coast University Hospital, Southport, Queensland, Australia|Toowoomba Hospital, Toowoomba, Queensland, Australia|Townsville Hospital, Townsville, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|The Queen Elizabeth Hospital, Adelaide, South Australia, Australia|Lyell McEwin Hospital, Adelaide, South Australia, Australia|Flinders Medical Centre, Bedford Park, South Australia, Australia|Launceston Hospital, Launceston, Tasmania, Australia|Ballarat Base Hospital, Ballarat, Victoria, Australia|Bendigo Hospital, Bendigo, Victoria, Australia|Casey Hospital, Berwick, Victoria, Australia|Box Hill Hospital, Box Hill, Victoria, Australia|Monash Medical Centre, Clayton, Victoria, Australia|Dandenong Hospital, Dandenong, Victoria, Australia|Angliss Hospital, Ferntree Gully, Victoria, Australia|Footscray Hospital, Footscray, Victoria, Australia|University Hosptial Geelong, Geelong, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Melbourne, Victoria, Australia|St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia|Maroondah Hospital, Ringwood East, Victoria, Australia|Sunshine Hospital, Sunshine, Victoria, Australia|Werribee Mercy Hospital, Werribee, Victoria, Australia|St John of God Hospital Midland, Midland, Western Australia, Australia|St John of God Hospital Murdoch, Murdoch, Western Australia, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|Sir Charles Gairdner Hospital, Perth, Western Australia, Australia|Fiona Stanley Hospital, Perth, Western Australia, Australia|St John of God Subiaco, Subiaco, Western Australia, Australia|AZ Sint-Jan, Brugge, Belgium|CHU de Charleroi - Hôpital Civil Marie Curie, Charleroi, Belgium|Universitair Ziekenhuis Antwerp, Edegem, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|Foothills Medical Centre, Calgary, Alberta, Canada|Peter Lougheed Centre, Calgary, Alberta, Canada|Rockyview General Hospital, Calgary, Alberta, Canada|South Health Campus, Calgary, Alberta, Canada|Royal Alexandra Hospital, Alberta, Edmonton, Alberta, Canada|University of Alberta Hospital, Edmonton, Alberta, Canada|Surrey Memorial Hospital, Surrey, British Columbia, Canada|St Boniface General Hospital, Winnipeg, Manitoba, Canada|Health Sciences Centre Winnipeg, Winnipeg, Manitoba, Canada|Grace Hospital, Winnipeg, Manitoba, Canada|Dr. Everett Chalmers Regional Hospital, Fredericton, New Brunswick, Canada|The Moncton Hospital, Fredericton, New Brunswick, Canada|The Saint John General Hospital, Fredericton, New Brunswick, Canada|William Osler Health System, Brampton, Ontario, Canada|Brantford General Hospital, Brantford, Ontario, Canada|Hamilton general Hospital, Hamilton, Ontario, Canada|Juravinski Hospital, Hamilton, Ontario, Canada|St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada|Kingston Health Sciences Centre, Kingston, Ontario, Canada|Grand River Hospital, Kitchener, Ontario, Canada|St Mary's General Hospital, Kitchener, Ontario, Canada|The Ottawa Hospital, Ottawa, Ontario, Canada|Niagara Health, Saint Catharines, Ontario, Canada|Thunder Bay General Hospital, Thunder Bay, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|St. Michael's Hospital Unity Health Toronto, Toronto, Ontario, Canada|Mount Sinai Hospital, Toronto, Ontario, Canada|Toronto General Hospital, Toronto, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|St Joseph's Health Centre, Toronto, Ontario, Canada|CIUSS Chaudieres-Appalaches (Levis), Lévis, Quebec, Canada|Hospital Maisonneuve-Rosemont, Montréal, Quebec, Canada|Hôpital Fleury, Montréal, Quebec, Canada|Centre Hospitalier de l'Universite de Montreal, Montréal, Quebec, Canada|McGill University Health Centre, Montréal, Quebec, Canada|Hopital du Sacre-Coeur de Montreal, Montréal, Quebec, Canada|CHU de Québec - Université Laval, Québec, Quebec, Canada|IUCPQ-UL, Québec, Quebec, Canada|Centre Hospitalier de l'Université de Sherbrooke, Sherbrooke, Quebec, Canada|Regina General Hospital, Saskatoon, Saskatchewan, Canada|Universidad de La Sabana, Chía, Cundinamarca, Colombia|General County Hospital Požega, Požega, Croatia|University Hospital Centre Zagreb, Zagreb, Croatia|University Hospital for Infectious Diseases, Zagreb, Croatia|Charité - Universitätsmedizin Berlin - Infektiologie und Pneumologie, Berlin, Germany|Charité - Universitätsmedizin Berlin - Nephrologie, Berlin, Germany|Vivantes Klinikum Neukölln, Berlin, Germany|Universitätsklinikum Köln, Cologne, Germany|Universitätsklinikum Frankfurt, Frankfurt, Germany|University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitätsklinikum Jena, Jena, Germany|Universitätsklinikum Leipzig, Leipzig, Germany|Universitäts Klinikum Tübingen, Tübingen, Germany|Universitätsklinikum Würzburg, Würzburg, Germany|Jósa András County Hospital, Nyíregyháza, Hungary|Csolnoky Ferenc Kórház - Veszprem County Hospital, Veszprém, Hungary|Almási Balogh Pál Kórház, Ózd, Hungary|Apollo Main Hospital, Chennai, Tamil Nadu, India|Apollo First Med Hospital, Chennai, Tamil Nadu, India|Apollo Vanagaram Hospital, Chennai, Tamil Nadu, India|Apollo Speciality Hospital - OMR, Chennai, Tamil Nadu, India|Beaumont Hospital, Dublin, Ireland|St. Vincent's University Hospital, Dublin, Ireland|University Hospital Galway, Galway, Ireland|St Marianna University School of Medicine, Kawasaki, Kanagawa, Japan|Yokohama City University Hospital, Yokohama, Kanagawa, Japan|St. Marianna University Yokohama City Seibu Hospital, Yokohama, Kanagawa, Japan|Saiseikai Kumamoto Hospital, Minami, Kumamoto, Japan|Osaka City General Hospital, Osaka, Japan|Nerima Hikarigaoka Hospital, Tokyo, Japan|Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan|Itabashi Chuo Medical Center, Tokyo, Japan|Tokyo bay Urayasu-Ichikawa Medical Center, Tokyo, Japan|Wakayama Medical University, Wakayama, Japan|Chitwan Medical College, Bharatpur, Nepal|Grande International Hospital, Kathmandu, Nepal|Hospital for Advanced Medicine and Surgery (HAMS), Kathmandu, Nepal|Nepal Mediciti, Kathmandu, Nepal|Meander Medisch Centrum, Amersfoort, Netherlands|Jeroen Bosch Ziekenhuis, Den Bosch, Netherlands|Martini Hospital Groningen, Groningen, Netherlands|University Medical Center Groningen, Groningen, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Canisius Wilhelmina Ziekenhuis, Nijmegen, Netherlands|Radboud University Medical Center, Nijmegen, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands|North Shore Hospital, Auckland, New Zealand|CVICU, Auckland City Hospital, Auckland, New Zealand|DCCM, Auckland City Hospital, Auckland, New Zealand|Middlemore Hospital, Auckland, New Zealand|Christchurch Hospital, Christchurch, New Zealand|Waikato Hospital, Hamilton, New Zealand|Taranaki Base Hospital, New Plymouth, New Zealand|Rotorua Hospital, Rotorua, New Zealand|Tauranga Hospital, Tauranga, New Zealand|Wellington Regional Hospital, Wellington, New Zealand|Whangarei Hospital, Whangarei, New Zealand|Ziauddin University Hospital Clifton Campus, Karachi, Sindh, Pakistan|Abbasi Shaheed Hospital, Karachi, Sindh, Pakistan|National Institute of Cardiovascular Diseases, Karachi, Karachi, Sindh, Pakistan|South City Hospital, Karachi, Karachi, Sindh, Pakistan|Ziauddin University North Nazimabad Campus, Karachi, Sindh, Pakistan|Centro Hospitalar do Medio Tejo, Abrantes, Portugal|Hospital Lusíadas Lisbon, Lisboa, Portugal|Clinical Hospital of Infectious and Tropical Diseases "Dr. Victor Babes", Bucharest, Romania|King Abdulaziz Medical City, Riyadh, Saudi Arabia|Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain|Hospital Universitario Reina Sofia, Córdoba, Spain|Basildon Hospital, Basildon, England, United Kingdom|Basingstoke and North Hampshire Hospital, Basingstoke, England, United Kingdom|Royal United Hospital, Bath, Bath, England, United Kingdom|Queen Elizabeth Hospital Birmingham, Birmingham, England, United Kingdom|Birmingham City Hospital, Birmingham, England, United Kingdom|Blackburn Hospital, Blackburn, England, United Kingdom|Pilgrim's Hospital, Boston, England, United Kingdom|Royal Bournemouth Hospital, Bournemouth, England, United Kingdom|Royal Sussex County Hospital, Brighton, England, United Kingdom|Southmead Hospital, Bristol, England, United Kingdom|Bristol Royal Hospital, Bristol, England, United Kingdom|Queen's Hospital, Burton, Burton on Trent, England, United Kingdom|Royal Papworth Hospital, Cambridge, England, United Kingdom|Addenbrookes Hospital, Cambridge, England, United Kingdom|Cumberland Royal Infirmary, Carlisle, England, United Kingdom|Ashford & St Peters Hospital Trust, Chertsey, England, United Kingdom|Chesterfield Royal Hospital, Chesterfield, England, United Kingdom|Countess of Chester Hospital, Chester, England, United Kingdom|Colchester Hospital, Colchester, England, United Kingdom|University Hospital Coventry, Coventry, England, United Kingdom|North Manchester General Hospital, Crumpsall, England, United Kingdom|Darlington Memorial Hospital, Darlington, England, United Kingdom|Darent Valley Hospital, Dartford, England, United Kingdom|Russells Hall Hospital, Dudley, England, United Kingdom|University Hospital of North Durham, Durham, England, United Kingdom|Royal Devon and Exeter Hospital, Exeter, England, United Kingdom|Frimley Park Hospital, Frimley, England, United Kingdom|Queen Elizabeth Hospital, Gateshead, England, United Kingdom|Medway Maritime Hospital, Gillingham, England, United Kingdom|James Paget Kings Lynn Hospital, Great Yarmouth, England, United Kingdom|Royal Surrey County Hospital, Guildford, England, United Kingdom|Northwick Park Hospital, Harrow, England, United Kingdom|Hereford County Hospital, Hereford, England, United Kingdom|Barnet Hospital, High Barnet, England, United Kingdom|Huddersfield Hospital, Huddersfield, England, United Kingdom|King George Hospital, Ilford, England, United Kingdom|Ipswich Hospital, Ipswich, England, United Kingdom|Kettering Hospital, Kettering, England, United Kingdom|Leeds Teaching Hospitals NHS Trust, Leeds, England, United Kingdom|Leicester Royal Infirmary, Leicester, England, United Kingdom|Glenfield Hospital, Leicester, England, United Kingdom|Lincoln County Hospital, Lincoln, England, United Kingdom|Liverpool Heart and Chest Hospital, Liverpool, England, United Kingdom|Alder Hey Hospital, Liverpool, England, United Kingdom|Royal Liverpool Hospital, Liverpool, England, United Kingdom|University Hospital Aintree, Liverpool, England, United Kingdom|Croydon University Hospital, London, England, United Kingdom|Royal London Hospital, London, England, United Kingdom|Whipps Cross Hospital, London, England, United Kingdom|Newham Hospital, London, England, United Kingdom|St Barts Hosptial, London, England, United Kingdom|North Middlesex Hospital, London, England, United Kingdom|Royal Free Hospital, London, England, United Kingdom|St Thomas' Hospital, London, England, United Kingdom|Guy's Hospital, London, England, United Kingdom|King's College Hospital, London, England, United Kingdom|St George's Hospital, London, England, United Kingdom|Royal Marsden Hospital, London, England, United Kingdom|Ryal Brompton, London, England, United Kingdom|Hammersmith Hospital, London, England, United Kingdom|St Mary's Hospital, London, England, United Kingdom|Charing Cross Hospital, London, England, United Kingdom|Luton and Dunstable University Hospital, Luton, England, United Kingdom|Maidstone Hospital - Maidstone and Tunbridge Wells NHS Trust, Maidstone, England, United Kingdom|Manchester Royal Infirmary, Manchester, England, United Kingdom|The Christie Hospital, Manchester, England, United Kingdom|Wythenshawe Hospital, Manchester, England, United Kingdom|Queen Elizabeth Hospital, Woolwich, Margate, England, United Kingdom|The James Cook University Hospital, Middlesbrough, England, United Kingdom|Milton Keynes University Hospital, Milton Keynes, England, United Kingdom|Royal Victoria Infirmary, Newcastle, Newcastle, England, United Kingdom|Newcastle Freeman Hospital, Newcastle, England, United Kingdom|Northampton General Hospital, Northampton, England, United Kingdom|Norfolk and Norwich University Hospital, Norwich, England, United Kingdom|City Hospital Nottingham, Nottingham, England, United Kingdom|Queen's Medical Centre - Nottingham University Hospitals NHS Trust, Nottingham, England, United Kingdom|George Eliot Hospital, Nuneaton, England, United Kingdom|Royal Oldham Hospital, Oldham, England, United Kingdom|Princess Royal University Hospital, Orpington, England, United Kingdom|John Radcliffe Hospital, Oxford, England, United Kingdom|Derriford Hospital, Plymouth, England, United Kingdom|Poole Hospital NHS Foundation Trust, Poole, England, United Kingdom|Queen Alexandra Hospital - Portsmouth Hospitals NHS Trust, Portsmouth, England, United Kingdom|Whiston Hospital, Prescot, England, United Kingdom|Royal Preston Hospital, Preston, England, United Kingdom|Royal Berkshire Hospital, Reading, England, United Kingdom|Alexandra Hospital, Redditch, Redditch, England, United Kingdom|Queen's Hospital Romford, Romford, England, United Kingdom|Rotherham General Hospital, Rotherham, England, United Kingdom|Salford Royal Hospital, Salford, England, United Kingdom|Salisbury District Hospital, Salisbury, England, United Kingdom|Royal Hallamshire Hospital, Sheffield, England, United Kingdom|Northern General Hospital, Sheffield, England, United Kingdom|Wexham Park Hospital, Slough, England, United Kingdom|South Tyneside District Hospital, South Shields, England, United Kingdom|Southampton General Hospital, Southampton, England, United Kingdom|Stepping Hill Hospital, Stockport, England, United Kingdom|University Hospital of North Tees, Stockton-on-Tees, England, United Kingdom|Royal Stoke University Hospital, Stoke-on-Trent, England, United Kingdom|Sunderland Hospital, Sunderland, England, United Kingdom|King's Mill Hospital, Sutton In Ashfield, England, United Kingdom|Great Western Hospital, Swindon, England, United Kingdom|Western General Hospital, Swindon, England, United Kingdom|Musgrove Park Hospital, Taunton, England, United Kingdom|Torbay and South Devon Hospital, Torquay, England, United Kingdom|Royal Cornwall Hospital, Truro, England, United Kingdom|Tunbridge Wells Hospital - Maidstone and Tunbridge Wells NHS Trust, Tunbridge Wells, England, United Kingdom|Harefield Hospital, Uxbridge, England, United Kingdom|Watford General Hospital, Watford, England, United Kingdom|Southend University Hospital, Westcliff-on-Sea, England, United Kingdom|West Cumberland Hospital, Whitehaven, England, United Kingdom|Royal Albert Edward Infirmary, Wigan, England, United Kingdom|Royal Hampshire Hospital, Winchester, England, United Kingdom|Arrow Park Hospital, Wirral, England, United Kingdom|New Cross Hospital, Wolverhampton, England, United Kingdom|Worcester Royal Hospital, Worcester, England, United Kingdom|York Hospital, York, England, United Kingdom|York Hospital, York, England, United Kingdom|Antrim Area Hospital, Antrim, Northern Ireland, United Kingdom|Royal Victoria Hospital, Belfast, Belfast, Northern Ireland, United Kingdom|Mater Hospital, Belfast, Northern Ireland, United Kingdom|Belfast City Hospital, Belfast, Northern Ireland, United Kingdom|Altnagelvin Hospital, Derry, Northern Ireland, United Kingdom|Aberdeen Royal Infirmary, Aberdeen, Scotland, United Kingdom|Ninewells Hospital, Dundee, Scotland, United Kingdom|Royal Infirmary of Edinburgh, Edinburgh, Scotland, United Kingdom|Glasgow Royal Infirmary, Glasgow, Scotland, United Kingdom|Queen Elizabeth University Hospital, Glasgow, Glasgow, Scotland, United Kingdom|Royal Alexandra Hospital, Glasgow, Paisley, Scotland, United Kingdom|Neville Hall Hospital, Abergavenny, Wales, United Kingdom|Glan Clywd Hospital, Bodelwyddan, Wales, United Kingdom|Princess of Wales Hospital, Bridgend, Wales, United Kingdom|University Hospital of Wales, Cardiff, Wales, United Kingdom|Glangwilli Hospital, Carmarthen, Wales, United Kingdom|Grange University Hospital, Cwmbran, Wales, United Kingdom|Royal Gwent Hospital, Newport, Wales, United Kingdom|Royal Glamorgan Hospital, Pontyclun, Wales, United Kingdom|Morriston Hospital, Swansea, Wales, United Kingdom|Wrexham Maelor Hospital, Wrexham, Wales, United Kingdom
- Study designs - Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 10000
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - All-cause mortality|Days alive and not receiving organ support in ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome
|
NCT04420988
|
Investigational COVID-19 Convalescent Plasma Infusion for Severely or Life-threateningly Ill COVID-19 Patients |
Available |
|
Jan/01/1970 |
Jan/01/1970 |
- Alternative id - Pro2020000746, Pro2020000911
- Interventions - Biological: COVID-19 Convalescent Plasma
- Study type - Expanded Access:Individual Patients|Intermediate-size Population
- Study results - No Results Available
- Locations - Rutgers New Jersey Medical School, Newark, New Jersey, United States|University Hospital, Newark, New Jersey, United States
- Study designs -
- Enrollment -
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures -
|
NCT04347681
|
Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19 |
Completed |
Phase 2 |
Apr/18/2020 |
Nov/16/2020 |
- Alternative id - HAEM0321
- Interventions - Other: convalescent plasma from recovered COVID 19 donor
- Study type - Interventional
- Study results - No Results Available
- Locations - John Hopkins Aramco Healthcare, Dhahran, Eastern Provence, Saudi Arabia|Dammam Medical Complex, Dammam, Saudi Arabia|Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia|king Fahad specialist hospital, Dammam, Saudi Arabia|DHahran Military Medical Complex, Dhahran, Saudi Arabia|International Medical Center, Jeddah, Saudi Arabia|Madinah General Hospital, Medina, Saudi Arabia|Ohud Hospital, Medina, Saudi Arabia|Taibah University, Medina, Saudi Arabia|Qatif Central Hospital, Qatif, Saudi Arabia|King Abdulaziz Medical City, Riyadh, Saudi Arabia|King Fahad Medical City, Riyadh, Saudi Arabia|King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia|King Khalid University Hospital, Riyadh, Saudi Arabia
- Study designs - Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 575
- Age - 18 Years to 85 Years (Adult, Older Adult)
- Outcome measures - ICU length of stay|Safety of convalescent plasma & Serious adverse reactions.|Number of days on mechanical ventilation|30 days of mortality|Days to clinical recovery .
|
NCT04569188
|
Convalescent Plasma in COVID-19 Elderly Patients |
Completed |
Phase 2 |
May/15/2020 |
Sep/03/2020 |
- Alternative id - Asstmantova
- Interventions - Biological: Convalescent plasma
- Study type - Interventional
- Study results - No Results Available
- Locations - Transfusion Service, Mantova, Italy
- Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 21
- Age - 65 Years and older (Older Adult)
- Outcome measures - Death|Viral load
|
NCT04381858
|
Convalescent Plasma vs Human Immunoglobulin to Treat COVID-19 Pneumonia |
Completed |
Phase 3 |
May/06/2020 |
Nov/26/2020 |
- Alternative id - 2020-A-10
- Interventions - Drug: Plasma from COVID-19 convalescent patient|Drug: Human immunoglobulin
- Study type - Interventional
- Study results - No Results Available
- Locations - Centenario Hospital Miguel Hidalgo, Aguascalientes, Mexico
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment
- Enrollment - 196
- Age - 16 Years to 90 Years (Child, Adult, Older Adult)
- Outcome measures - Mean hospitalization time|Mean Oxigenation index evolution|Rate of severe ARDS|Rate and time to dead|Mean time with invasive mechanical ventilation|Time to Viral PCR Negativization
|
NCT04554992
|
Convalescent Plasma for the Treatment of COVID-19 (Coronavirus Disease 2019) |
Active, not recruiting |
Phase 1 |
Mar/20/2020 |
Jun/01/2022 |
- Alternative id - 00025121
- Interventions - Biological: COVID 19 Convalescent Plasma
- Study type - Interventional
- Study results - No Results Available
- Locations - Houston Methodist Hopsital, Houston, Texas, United States
- Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 350
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Cumulative incidence of serious adverse events related to the treatment intervention.|Mortality at Day 28 post-hospital admission.|Length of hospital stay|Length of supplemental oxygen requirement.|Length of mechanical ventilation requirement.|Length of ICU stay
|
NCT04474340
|
COVID-19 Convalescent Plasma Treatment in SARS-CoV-2 Infected Patients |
Recruiting |
Phase 1 |
May/21/2020 |
Dec/30/2020 |
- Alternative id - MOHKuwait
- Interventions - Drug: COVID-19 Convalscent Plasma
- Study type - Interventional
- Study results - No Results Available
- Locations - Ministry Of Health, Kuwait, Kuwait
- Study designs - Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 300
- Age - 15 Years to 85 Years (Child, Adult, Older Adult)
- Outcome measures - Time to clinical improvement|All cause mortality
|
NCT04539275
|
COVID-19 (VA CURES-1) |
Terminated |
Phase 3 |
Nov/16/2020 |
Sep/30/2021 |
- Alternative id - COVID19-8900-22
- Interventions - Drug: Convalescent Plasma|Other: Masked Saline Placebo
- Study type - Interventional
- Study results - No Results Available
- Locations - Birmingham VA Medical Center, Birmingham, AL, Birmingham, Alabama, United States|Phoenix VA Health Care System, Phoenix, AZ, Phoenix, Arizona, United States|Rocky Mountain Regional VA Medical Center, Aurora, CO, Aurora, Colorado, United States|North Florida/South Georgia Veterans Health System, Gainesville, FL, Gainesville, Florida, United States|Orlando VA Medical Center, Orlando, FL, Orlando, Florida, United States|James A. Haley Veterans' Hospital, Tampa, FL, Tampa, Florida, United States|Atlanta VA Medical and Rehab Center, Decatur, GA, Decatur, Georgia, United States|Edward Hines Jr. VA Hospital, Hines, IL, Hines, Illinois, United States|VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor, Michigan, United States|John D. Dingell VA Medical Center, Detroit, MI, Detroit, Michigan, United States|VA Southern Nevada Healthcare System, North Las Vegas, NV, North Las Vegas, Nevada, United States|James J. Peters VA Medical Center, Bronx, NY, Bronx, New York, United States|Durham VA Medical Center, Durham, NC, Durham, North Carolina, United States|Louis Stokes VA Medical Center, Cleveland, OH, Cleveland, Ohio, United States|Oklahoma City VA Medical Center, Oklahoma City, OK, Oklahoma City, Oklahoma, United States|VA Portland Health Care System, Portland, OR, Portland, Oregon, United States|Ralph H. Johnson VA Medical Center, Charleston, SC, Charleston, South Carolina, United States|VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX, Dallas, Texas, United States|Michael E. DeBakey VA Medical Center, Houston, TX, Houston, Texas, United States|South Texas Health Care System, San Antonio, TX, San Antonio, Texas, United States|VA Salt Lake City Health Care System, Salt Lake City, UT, Salt Lake City, Utah, United States|Hunter Holmes McGuire VA Medical Center, Richmond, VA, Richmond, Virginia, United States|William S. Middleton Memorial Veterans Hospital, Madison, WI, Madison, Wisconsin, United States|VA Caribbean Healthcare System, San Juan, PR, San Juan, Puerto Rico
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
- Enrollment - 75
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Proportion of participants developing acute hypoxemic respiratory failure or all-cause death|Time (in days) to recovery|Time (in days) to death or respiratory failure|Proportion of patients who died from any cause, had respiratory failure, or required humidified heated high-flow nasal cannula (HHHFNC) at 15 Lpm|Time (in days) to death or respiratory failure or HHHFNC at 15 Lpm|Subject 28-day all-cause mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Participant's clinical status by ordinal scale|Mean change in the ordinal scale|Time to discharge or to a National Early Warning Score (NEWS)-2 of = 2 and maintained for 24 hours, whichever occurs first|Change in NEWS-2 Score from Day 1 (baseline) to Days 2, 4, 7, 11, 15, and 29|Duration of hospitalization|Number of hospitalizations related to COVID-19|Cumulative incidence of Serious Adverse Events (SAEs)|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Incidence of discontinuation or temporary suspension of study product administrations (for any reason)|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in total bilirubin|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in prothrombin time (PT)
|
NCT04325672
|
Convalescent Plasma to Limit Coronavirus Associated Complications |
Withdrawn |
Phase 2 |
Apr/01/2020 |
Dec/31/2022 |
- Alternative id - 20-002864
- Interventions - Biological: Convalescent Plasma
- Study type - Interventional
- Study results - No Results Available
- Locations -
- Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science
- Enrollment - 0
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - RNA in SARS-CoV-2|ICU Admissions|Hospital Mortality|Hospital Length of Stay (LOS)|Type of respiratory support|Duration of respiratory support
|
NCT04600440
|
Convalescent Plasma in the Treatment of Covid-19 |
Recruiting |
Not Applicable |
Apr/25/2020 |
Feb/28/2022 |
- Alternative id - Covid convalescent plasma
- Interventions - Biological: Convalescent plasma
- Study type - Interventional
- Study results - No Results Available
- Locations - Skåne University Hospital, Lund, Sweden
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 100
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Number of days in need of oxygen|Number of days before discharge from hospital|Mortality within 3 months|Number of days before need of assisted ventilation
|
NCT04358211
|
Expanded Access to Convalescent Plasma to Treat and Prevent Pulmonary Complications Associated With COVID-19 |
No longer available |
|
Jan/01/1970 |
Jan/01/1970 |
- Alternative id - 2020-595
- Interventions - Biological: Biological: COVID-19 convalescent plasma
- Study type - Expanded Access:Intermediate-size Population|Treatment IND/Protocol
- Study results - No Results Available
- Locations - Tulane Medical Center, New Orleans, Louisiana, United States
- Study designs -
- Enrollment -
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures -
|
NCT04545047
|
Observational Study of Convalescent Plasma for Treatment of Veterans With COVID-19 |
Active, not recruiting |
|
May/01/2020 |
Jun/30/2022 |
- Alternative id - 2030
- Interventions - Biological: COVID-19 convalescent plasma
- Study type - Observational
- Study results - No Results Available
- Locations - VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston, Massachusetts, United States|VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle, Washington, United States
- Study designs - Observational Model: Other|Time Perspective: Prospective
- Enrollment - 4755
- Age - 21 Years to 80 Years (Adult, Older Adult)
- Outcome measures - All-cause mortality
|
NCT04463823
|
"NORPLASMA" Covid-19 Convalescent Plasma Treatment Monitoring Study |
Recruiting |
|
Jul/06/2020 |
May/31/2025 |
- Alternative id - 148622
- Interventions -
- Study type - Observational
- Study results - No Results Available
- Locations - Helse Fonna, Haugesund, Norway|Sorlandet hospital, Kristiansand, Norway|Akershus University Hospital, Lørenskog, Norway|Oslo University Hospital, Oslo, Norway|Sykehuset Ostfold, Sarpsborg, Norway|Sykehuset Telemark, Skien, Norway|St.Olavs Hospital, Trondheim, Norway
- Study designs - Observational Model: Case-Only|Time Perspective: Prospective
- Enrollment - 500
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - observation
|
NCT04344535
|
Convalescent Plasma vs. Standard Plasma for COVID-19 |
Terminated |
Phase 1|Phase 2 |
Apr/08/2020 |
Feb/01/2021 |
- Alternative id - SBU-COVID19-ConvalescentPlasma
- Interventions - Biological: Convalescent Plasma|Biological: Standard Donor Plasma
- Study type - Interventional
- Study results - Has Results
- Locations - Stony Brook University Hospital, Stony Brook, New York, United States
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
- Enrollment - 82
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - 28 Day Ventilator Free Days|90 Day All-cause Mortality
|
NCT04438694
|
Assessment of the Effect of Convalescent Plasma Therapy in Patients With Life-threatening COVID19 Infection |
Recruiting |
Phase 1|Phase 2 |
Jun/01/2020 |
Dec/31/2021 |
- Alternative id - N39-2020
- Interventions - Biological: Convalescent Plasma|Drug: Standard of Care
- Study type - Interventional
- Study results - No Results Available
- Locations - Cairo University Hospital, Cairo, Egypt
- Study designs - Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 67
- Age - 21 Years to 70 Years (Adult, Older Adult)
- Outcome measures - Duration of hospitalization/Recovery status
|
NCT04384497
|
Convalescent Plasma for Treatment of COVID-19: An Exploratory Dose Identifying Study |
Completed |
Phase 1|Phase 2 |
May/07/2020 |
Dec/01/2020 |
- Alternative id - CP2
- Interventions - Biological: SARS-CoV-2 convalescent plasma
- Study type - Interventional
- Study results - No Results Available
- Locations - Danderyd Hospital, Danderyd, Stockholm, Sweden|Karolinska University Hospital, Stockholm, Sweden
- Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 10
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Number and proportion of patients with progression to ventilation or sustained requirement of supplementary oxygen therapy|Adverse events|Dose of plasma needed to clear viremia|Clearance of viremia|Fever and symptoms|Inflammatory parameters|Antibody response to SARS-CoV-2
|
NCT04456413
|
Convalescent Plasma as Treatment for Subjects With Early COVID-19 Infection |
Recruiting |
Phase 2 |
Nov/06/2020 |
Nov/01/2023 |
- Alternative id - Pro2020-0542
- Interventions - Biological: Convalescent Plasma|Other: Best Supportive Care
- Study type - Interventional
- Study results - No Results Available
- Locations - Hackensack University Medical Center, Hackensack, New Jersey, United States
- Study designs - Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 306
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Hospitalization Rate|Time to symptoms resolution|Overall survival|Rate of virologic clearance by nasopharyngeal swab at 2 and 4 weeks|Rate of nasopharyngeal swab positivity in donors|Rate of donor titers level|Impact of donor titers level on efficacy|Patients' anti-SARS-CoV2 titer assessment pre-infusion for the Treatment group, at 2 weeks , 4 weeks and 2 months.
|
NCT04884477
|
COVID-19 Infection in Patients Receiving Anti-CD20 Therapy |
Active, not recruiting |
|
Jun/01/2021 |
Jun/30/2022 |
- Alternative id - 21-001374
- Interventions - Biological: Convalescent Plasma
- Study type - Observational
- Study results - No Results Available
- Locations - Mayo Clinic, Rochester, Minnesota, United States
- Study designs - Observational Model: Cohort|Time Perspective: Retrospective
- Enrollment - 342
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Change in WHO Clinical Progression scale|90-day mortality|ICU-free days
|
NCT04353206
|
Convalescent Plasma in ICU Patients With COVID-19-induced Respiratory Failure |
Terminated |
Early Phase 1 |
Jun/27/2020 |
Nov/01/2020 |
- Alternative id - Acute Care CP Consortium Trial
- Interventions - Biological: Multiple Doses of Anti-SARS-CoV-2 convalescent plasma
- Study type - Interventional
- Study results - No Results Available
- Locations - 8700 Beverly Blvd., Los Angeles, California, United States|Johns Hopkins University, Baltimore, Maryland, United States
- Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 6
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Proportion of subjects who consent to the study and receive at least one dose of convalescent plasma.|Overall survival of patients in the ICU receiving at least once dose of convalescent plasma for Covid-19-induced respiratory failure.
|
NCT04445207
|
Experimental Expanded Access Treatment With Convalescent Plasma for the Treatment of Patients With COVID-19 |
Available |
|
Jan/01/1970 |
Jan/01/1970 |
- Alternative id - H000020420
- Interventions - Biological: Convalescent Plasma
- Study type - Expanded Access:Treatment IND/Protocol
- Study results - No Results Available
- Locations - UMass Medical School, Worcester, Massachusetts, United States
- Study designs -
- Enrollment -
- Age - 12 Years and older (Child, Adult, Older Adult)
- Outcome measures -
|
NCT04418518
|
A Trial of CONvalescent Plasma for Hospitalized Adults With Acute COVID-19 Respiratory Illness |
Recruiting |
Phase 3 |
Jun/24/2020 |
Dec/01/2021 |
- Alternative id - 20-04021981
- Interventions - Biological: Convalescent plasma
- Study type - Interventional
- Study results - No Results Available
- Locations - Brooklyn Methodist Hospital, Brooklyn, New York, United States|Weill Cornell Medicine, New York, New York, United States|Lower Manhattan Hospital, New York, New York, United States
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 1200
- Age - 18 Years to 70 Years (Adult, Older Adult)
- Outcome measures - Intubation or death in hospital|Need for Intubation|Time to intubation|Ventilator-free days|In-hospital death|Time to in-hospital death|Death at 30 days|Length of stay in intensive care unit (ICU)|Length of stay in hospital|Need for extracorpeal membrane oxygenation (ECMO)|Need for renal replacement therapy|Development of myocarditis|Adverse events and serious adverse events|CCP transfusion-associated adverse events (AE)
|
NCT04712344
|
Assessment of Efficacy and Safety of Therapy With COVID-19 Convalescent Plasma in Subjects With Severe COVID-19 (IPCO) |
Recruiting |
Phase 2 |
Jan/18/2021 |
Sep/01/2021 |
- Alternative id - UKER-COV2-01
- Interventions - Biological: COVID-19 convalescent plasma
- Study type - Interventional
- Study results - No Results Available
- Locations - University Hospital Erlangen, Erlangen, Germany
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 58
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Change in SOFA score from Baseline Visit|Assessment of impact of immune therapy with COVID-19 convalescent plasma on markers for ARDS due to severe COVID-19 infection|Assessment of impact of immune therapy with COVID-19 convalescent plasma on short-term all-cause mortality|Assessment of impact of immune therapy with COVID-19 convalescent plasma on oxygen supply in patients with ARDS due to severe COVID-19|Assessment of impact of immune therapy with COVID-19 convalescent plasma on oxygen demand in patients with ARDS due to severe COVID-19|Assessment of impact of immune therapy with COVID-19 convalescent plasma on Duration of Oxygen supply in patients with ARDS due to severe COVID-19|Assessment of impact of immune therapy with COVID-19 convalescent plasma on PEEP in patients with ARDS due to severe COVID-19|Assessment of impact of immune therapy with COVID-19 convalescent plasma on FiO2 in patients with ARDS due to severe COVID-19|Assessment of impact of immune therapy with COVID-19 convalescent plasma on driving pressure in patients with ARDS due to severe COVID-19|Assessment of impact of immune therapy with COVID-19 convalescent plasma on Duration of invasive mechanical Ventilation in patients with ARDS due to severe COVID-19
|
NCT04355767
|
Convalescent Plasma in Outpatients With COVID-19 |
Completed |
Phase 3 |
Aug/11/2020 |
Mar/29/2021 |
- Alternative id - C3PO|1OT2HL156812-01
- Interventions - Biological: Convalescent Plasma|Biological: Saline
- Study type - Interventional
- Study results - Has Results
- Locations - Chandler Regional Medical Center, Chandler, Arizona, United States|Valleywise Health Medical Center, Phoenix, Arizona, United States|UCSD Health La Jolla, La Jolla, California, United States|Loma Linda University Medical Center, Loma Linda, California, United States|Ronald Reagan UCLA Medical Center, Los Angeles, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|UC Davis Medical Center, Sacramento, California, United States|Stanford University, Stanford, California, United States|Harbor-UCLA Medical Center, Torrance, California, United States|University of Colorado Hospital, Aurora, Colorado, United States|UF Health Shands Hospital, Gainesville, Florida, United States|Jackson Memorial Hospital, Miami, Florida, United States|Grady Memorial Hospital, Atlanta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Illinois Hospital, Chicago, Illinois, United States|University of Chicago Medical Center, Chicago, Illinois, United States|University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States|University of Louisville Hospital, Louisville, Kentucky, United States|Maine Medical Center, Portland, Maine, United States|Tufts Medical Center, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Newton-Wellesley Hospital, Newton, Massachusetts, United States|Baystate Medical Center, Springfield, Massachusetts, United States|University of Michigan University Hospital, Ann Arbor, Michigan, United States|Detroit Receiving Hospital, Detroit, Michigan, United States|Harper University Hospital, Detroit, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Sinai-Grace Hospital, Detroit, Michigan, United States|Spectrum Health Hospitals Butterworth Hospital, Grand Rapids, Michigan, United States|William Beaumont Hospital, Royal Oak, Michigan, United States|William Beaumont Hospital-Troy, Troy, Michigan, United States|HealthPartners Methodist Hospital, Saint Louis Park, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|Barnes Jewish Hospital, Saint Louis, Missouri, United States|Cooper University Hospital, Camden, New Jersey, United States|Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States|University of New Mexico Hospital, Albuquerque, New Mexico, United States|SUNY Downstate Medical Center, Brooklyn, New York, United States|Duke University Hospital, Durham, North Carolina, United States|Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|OSU Wexner Medical Center, Columbus, Ohio, United States|Mercy St. Vincent Medical Center, Toledo, Ohio, United States|Oregon Health & Science University Hospital, Portland, Oregon, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|Einstein Medical Center, Philadelphia, Pennsylvania, United States|UPMC Presbyterian Hospital, Pittsburgh, Pennsylvania, United States|William P. Clements Jr. University Hospital, Dallas, Texas, United States|Ben Taub General Hospital, Houston, Texas, United States|Memorial Hermann Texas Medical Center, Houston, Texas, United States|University of Utah Healthcare, Salt Lake City, Utah, United States|Froedtert Hospital, Milwaukee, Wisconsin, United States
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment
- Enrollment - 511
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Number of Patients With Disease Progression (Intention-to-treat Population)|Number of Patients With Disease Progression (Per-protocol Population)|Worst Severity Rating on the WHO COVID Ordinal Scale for Clinical Improvement During the 30 Days Following Randomization|Number of Patients With Worsening of Symptoms at Day 15 as a Measure of Time to Disease Progression|Number of Hospital-free Days During the 30 Days Following Randomization|All-cause Mortality
|
NCT04373460
|
Convalescent Plasma to Limit SARS-CoV-2 Associated Complications |
Active, not recruiting |
Phase 2 |
Jun/03/2020 |
Jan/31/2023 |
- Alternative id - IRB00247590
- Interventions - Biological: SARS-CoV-2 convalescent plasma|Biological: Plasma from a volunteer donor
- Study type - Interventional
- Study results - No Results Available
- Locations - University of Alabama at Birmingham, Birmingham, Alabama, United States|Mayo Clinic, Phoenix, Phoenix, Arizona, United States|Center for American Indian Health - Whiteriver Office, Whiteriver, Arizona, United States|University of California, Los Angeles, Los Angeles, California, United States|University of California, Irvine Health, Orange, California, United States|Western Connecticut Health Netowrk, Danbury Hospital, Danbury, Connecticut, United States|Western Connecticut Health Network, Norwalk Hospital, Norwalk, Connecticut, United States|University of Miami, Coral Gables, Florida, United States|University of Miami Clinical Translational Research Site, Miami, Florida, United States|NorthShore University HealthSystem, Evanston, Illinois, United States|Anne Arundel Medical Center, Annapolis, Maryland, United States|The Johns Hopkins University, Baltimore, Maryland, United States|MedStar Washington Hospital Center, Hyattsville, Maryland, United States|University of Massachusetts Worcester, Worcester, Massachusetts, United States|Wayne State University, Detroit, Michigan, United States|University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States|Center for American Indian Health - Gallup Office, Gallup, New Mexico, United States|Center for American Indian Health - Shiprock Office, Shiprock, New Mexico, United States|Vassar Brothers Medical Center, Poughkeepsie, New York, United States|University of Rochester, Rochester, New York, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|Lifespan/BrownUniversity (Rhode Island Hospital), Providence, Rhode Island, United States|Baylor College of Medicine, Houston, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States|The University of Utah, Salt Lake City, Utah, United States
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
- Enrollment - 1344
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Cumulative incidence of hospitalization or death prior to hospitalization|Cumulative incidence of treatment-related serious adverse events|Cumulative incidence of treatment-related grade 3 or higher adverse events|Change in serum SARS-CoV-2 antibody titers|Time to SARS-CoV-2 Polymerase Chain Reaction (PCR) negativity
|
NCT04374370
|
SARSCoV2 (COVID-19) Convalescent Plasma (CP) Expanded Access Protocol (EAP) |
No longer available |
|
Jan/01/1970 |
Jan/01/1970 |
- Alternative id - 1596191
- Interventions - Biological: SARSCoV2 Convalescent Plasma
- Study type - Expanded Access:Intermediate-size Population
- Study results - No Results Available
- Locations - AdventHealth Orlando, Orlando, Florida, United States
- Study designs -
- Enrollment -
- Age - 6 Years to 99 Years (Child, Adult, Older Adult)
- Outcome measures -
|
NCT04535063
|
Convalescent Plasma as Potential Therapy for Severe COVID-19 Pneumonia |
Recruiting |
Phase 3 |
Apr/18/2020 |
Feb/25/2021 |
- Alternative id - RValentini
- Interventions - Biological: COVID19 convalescent plasma infusion
- Study type - Interventional
- Study results - No Results Available
- Locations - Centro de Educación Médica e Investigaciones Clínicas, Buenos Aires, Argentina
- Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 200
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - 28 days survival|efficacy of plasma infusion according to antibodies levels in the infuse bags|clinical efficacy of plasma infusion according to frame time from symptoms onset and hospitalization|change in clinical WHO ordinal scale from 1 to 10 points
|
NCT04438057
|
Evaluating the Efficacy of Convalescent Plasma in Symptomatic Outpatients Infected With COVID-19 |
Recruiting |
Phase 2 |
Aug/12/2020 |
Aug/12/2021 |
- Alternative id - MIDC-CCP
- Interventions - Biological: CCP
- Study type - Interventional
- Study results - No Results Available
- Locations - Metro Infectious Disease Consultants, Burr Ridge, Illinois, United States
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 150
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Time to Resolution of Symptoms|SAEs within 24 hours of plasma infusion|Decrease in Inflammatory Markers|Hospitalization within 28 days
|
NCT04361253
|
Evaluation of SARS-CoV-2 (COVID-19) Antibody-containing Plasma thErapy |
Terminated |
Phase 3 |
Apr/30/2020 |
Jun/30/2021 |
- Alternative id - 2020P001215
- Interventions - Biological: High-Titer COVID-19 Convalescent Plasma (HT-CCP)|Biological: Standard Plasma (FFP)
- Study type - Interventional
- Study results - No Results Available
- Locations - Brigham and Women's Hospital, Boston, Massachusetts, United States
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
- Enrollment - 45
- Age - 12 Months and older (Child, Adult, Older Adult)
- Outcome measures - Modified WHO Ordinal Scale (MOS) score
|
NCT04356482
|
CONVALESCENT PLASMA FOR ILL PATIENTS BY COVID-19 |
Recruiting |
Phase 1|Phase 2 |
May/20/2020 |
Dec/01/2020 |
- Alternative id - TERAPLASCOV2
- Interventions - Biological: convalescent plasma
- Study type - Interventional
- Study results - No Results Available
- Locations - Hospital Del Issste Regional En Guadalajara Jalisco, Guadalajara, Jalisco, Mexico|Secretaria de Salud Del Estado de Sonora, Hospital General Del Estado, Hermosillo, Sonora, Mexico|Hospital Central Norte Pemex, Mexico City, Mexico
- Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 90
- Age - 16 Years and older (Child, Adult, Older Adult)
- Outcome measures - Clinical improvement|improvement in tomographic image|test positivity for COVID-19|early and late complications associated to convalescent plasma|days at ICU
|
NCT04357106
|
COPLA Study: Treatment of Severe Forms of COronavirus Infection With Convalescent PLAsma |
Recruiting |
Phase 2 |
Apr/13/2020 |
Aug/01/2020 |
- Alternative id - CHMI-030420-01
- Interventions - Biological: Convalescent plasma
- Study type - Interventional
- Study results - No Results Available
- Locations - Centro de Hematología y Medicina Interna, Puebla, Mexico
- Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 10
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Lung injury|Overall survival|Adverse reactions to plasma
|
NCT04323800
|
Convalescent Plasma to Stem Coronavirus (CSSC-001) |
Completed |
Phase 2 |
Jun/10/2020 |
Jun/22/2021 |
- Alternative id - IRB00245634
- Interventions - Biological: Anti- SARS-CoV-2 Plasma|Biological: SARS-CoV-2 non-immune Plasma
- Study type - Interventional
- Study results - No Results Available
- Locations - University of Alabama at Birmingham, Birmingham, Alabama, United States|Center for American Indian Health - Whiteriver Office, Whiteriver, Arizona, United States|University of California, San Diego, La Jolla, California, United States|University of California, Los Angeles, Los Angeles, California, United States|University of California, Irvine Health, Orange, California, United States|Western Connecticut Health Network, Danbury Hospital, Danbury, Connecticut, United States|Western Connecticut Health Netowrk, Norwalk Hospital, Norwalk, Connecticut, United States|MedStar Georgetown University Hospital, Washington, District of Columbia, United States|University of Miami, Coral Gables, Florida, United States|University of Miami Clinical Translational Research Site, Miami, Florida, United States|NorthShore University HealthSystem, Evanston, Illinois, United States|Anne Arundel Medical Center, Annapolis, Maryland, United States|The Johns Hopkins University, Baltimore, Maryland, United States|University of Massachusetts Worcester, Worcester, Massachusetts, United States|Wayne State University, Detroit, Michigan, United States|University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States|Center for American Indian Health - Gallup Office, Gallup, New Mexico, United States|Center for American Indian Health - Shiprock Office, Shiprock, New Mexico, United States|Vassar Brothers Medical Center, Poughkeepsie, New York, United States|University of Rochester, Rochester, New York, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|Lifespan/BrownUniversity (Rhode Island Hospital), Providence, Rhode Island, United States|Baylor College of Medicine, Houston, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States|The University of Utah, Salt Lake City, Utah, United States
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
- Enrollment - 180
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Efficacy of treatment at Day 28|Safety of treatment with high-titer Anti- SARS-CoV-2 plasma versus control - 1|Safety of treatment with high-titer Anti- SARS-CoV-2 plasma versus control - 2|Cumulative incidence of disease severity
|
NCT04354831
|
A Study Evaluating the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma in Hospitalized Patients With COVID-19 Infection |
Active, not recruiting |
Phase 2 |
May/11/2020 |
May/01/2023 |
- Alternative id - PRO00037712
- Interventions - Biological: anti-SARS-CoV-2 convalescent plasma
- Study type - Interventional
- Study results - No Results Available
- Locations - Froedtert Hospital, Milwaukee, Wisconsin, United States
- Study designs - Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 131
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Overall Mortality within 60 days|Length of ICU stay during current admission for COVID
|
NCT04403477
|
Convalescent Plasma Therapy in Severe COVID-19 Infection |
Recruiting |
Phase 2 |
May/20/2020 |
Oct/30/2020 |
- Alternative id - BSMMU/2020/6104
- Interventions - Biological: Convalescent plasma
- Study type - Interventional
- Study results - No Results Available
- Locations - Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 20
- Age - 16 Years and older (Child, Adult, Older Adult)
- Outcome measures - Proportion of In-hospital mortality|Time to death|Fever|Respiratory distress|Saturation of oxygen|Blood pressure|Oxygen requirement|C-reactive Protein|Ferritin|SGPT|SGOT|ICU stay|Ventilator support|Hospital stay|Proportion of Transfusion reaction
|
NCT04343261
|
Convalescent Plasma in the Treatment of COVID 19 |
Completed |
Phase 2 |
Apr/10/2020 |
Aug/13/2020 |
- Alternative id - SFH-20-23
- Interventions - Biological: Convalescent Plasma
- Study type - Interventional
- Study results - Has Results
- Locations - Trinity Health Of New England, Hartford, Connecticut, United States
- Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 48
- Age - 18 Years to 90 Years (Adult, Older Adult)
- Outcome measures - Mortality|Viral Load|Serum Antibody Titers
|
NCT04393727
|
Transfusion of Convalescent Plasma for the Early Treatment of Patients With COVID-19 |
Terminated |
Phase 2 |
May/01/2020 |
Sep/30/2020 |
- Alternative id - TSUNAMI
- Interventions - Biological: CONVALESCENT PLASMA
- Study type - Interventional
- Study results - No Results Available
- Locations - Azienda Ospedaliero Universitaria Pisana, Pisa, Italy
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 1
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Need of invasive mechanical ventilation|Mortality rates|Time to invasive mechanical ventilation|Time to virologic cure|Length of hospital stay|Adverse events
|
NCT04492501
|
Investigational Treatments for COVID-19 in Tertiary Care Hospital of Pakistan |
Completed |
Not Applicable |
Apr/01/2020 |
Jul/20/2020 |
- Alternative id - Sultan Mehmood Kamran 3
- Interventions - Procedure: Therapeutic Plasma exchange|Biological: Convalescent Plasma|Drug: Tocilizumab|Drug: Remdesivir|Biological: Mesenchymal stem cell therapy
- Study type - Interventional
- Study results - No Results Available
- Locations - Pak Emirates Military Hospital, Rawalpindi, Punjab, Pakistan
- Study designs - Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 600
- Age - 18 Years to 90 Years (Adult, Older Adult)
- Outcome measures - survival|duration of hospitalization|Time to resolution of cytokine release storm|Time of viral clearance|Complications
|
NCT04542941
|
Assessment of Safety and Efficacy of CCP |
Completed |
Not Applicable |
Jun/16/2020 |
Dec/31/2020 |
- Alternative id - CCP
- Interventions - Biological: COVID Convalescent Plasma
- Study type - Interventional
- Study results - No Results Available
- Locations - Mulago Specialised Hospital, Kampala, Uganda
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 136
- Age - 18 Years to 100 Years (Adult, Older Adult)
- Outcome measures - Time to viral clearance (RT-PCR negativity)|Time to symptom resolution|Time to severe/critical disease|Number of participants reporting an adverse event as evidenced by clinical manifestations
|
NCT04442191
|
Convalescent Plasma as a Possible Treatment for COVID-19 |
Recruiting |
Phase 2 |
May/05/2020 |
May/05/2021 |
- Alternative id - 2020-0441
- Interventions - Biological: Convalescent plasma|Biological: Placebo
- Study type - Interventional
- Study results - No Results Available
- Locations - University of Illinois at Chicago, Chicago, Illinois, United States
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
- Enrollment - 50
- Age - 40 Years and older (Adult, Older Adult)
- Outcome measures - Oxygen supplementation|28-day and in-hospital mortality rate|Number of participants transferred to the Intensive Care Unit (ICU)|Number of participants intubated|Length of hospital stay in days|Type of respiratory support|C-reactive Protein (CRP)|Lymphocyte count|Length or respiratory support required, in days|Lactate dehydrogenase (LDH)|Ferritin|D-Dimer|White Blood Cell (WBC) Count
|
NCT04634422
|
Plasma Exchange (PLEX) and Convalescent Plasma (CCP) in COVID-19 Patients With Multiorgan Failure |
Recruiting |
Not Applicable |
Nov/16/2020 |
Jun/30/2022 |
- Alternative id - H-20041716
- Interventions - Procedure: Plasma exchange and convalescent plasma
- Study type - Interventional
- Study results - No Results Available
- Locations - Rigshospitalet, Copenhagen, Denmark
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 220
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Alive at Day 90th|Day 8 serious adverse events|Day 28 all cause mortality|Days alive without life support at day 90
|
NCT04397523
|
Efficacy and Safety of COVID-19 Convalescent Plasma |
Completed |
Not Applicable |
Apr/30/2020 |
May/10/2021 |
- Alternative id - ITM05/2020MKD
- Interventions - Biological: anti-SARS-CoV-2 convalescent plasma
- Study type - Interventional
- Study results - No Results Available
- Locations - Institute for Transfusion Medicine of RNM, Skopje, North Macedonia
- Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 200
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Duration of oxygenation and ventilation support|Hospital length of stay (LOS)|ICU admission|Ventilator free days|Incidence of serious adverse events|Type of respiratory support|Number of participants with different clinical outcomes including death, critical illness and recovery
|
NCT04565197
|
Convalescent Plasma Therapy for COVID-19 Patients |
Active, not recruiting |
Early Phase 1 |
May/01/2020 |
Dec/30/2020 |
- Alternative id - LGH008
- Interventions - Biological: convalescent plasma
- Study type - Interventional
- Study results - No Results Available
- Locations - Muhammad Irfan Malik, Lahore, Punjab, Pakistan
- Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 20
- Age - 15 Years to 80 Years (Child, Adult, Older Adult)
- Outcome measures - clinical outcome after plasma therapy|Clinical response to treatment
|
NCT05077930
|
Convalescent Plasma Therapy for Hospitalized Patients With COVID-19 |
Recruiting |
Phase 2 |
Oct/01/2021 |
Jan/01/2022 |
- Alternative id - CCP TRIAL
- Interventions - Biological: Convalescent plasma|Drug: Standard of care
- Study type - Interventional
- Study results - No Results Available
- Locations - Maternidade e Cirurgia Nossa Senhora do Rocio/ SA - Hospital do Rocio, Campo Largo, Paraná, Brazil
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 200
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Clinical status on a 7-point ordinal scale|Percentage of participants at each clinical status on a 7-point ordinal scale|Oxygen saturation|Prevalence of oxygen-intake methods|Respiratory rate|The PaO2 / FiO2 ratio (for patients on mechanical mechanisms)|Number and /or extension of affected lung areas on chest computed tomography|Length of hospital stay|Length of stay in intensive care|Time until independence from oxygen therapy in days|Ventilator free days|In patients who needed mechanical ventilation, time to initiate mechanical ventilation (calculated in days, from entry into the protocol until orotracheal intubation)|Rate of transfusion reactions to convalescent plasma infusion|Percentage of participants who develop serious adverse events and adverse events considered as definitely or probably associated with plasma transfusion
|
NCT04352751
|
Experimental Use of Convalescent Plasma for Passive Immunization in Current COVID-19 Pandemic in Pakistan in 2020 |
Recruiting |
Not Applicable |
May/01/2020 |
Apr/01/2021 |
- Alternative id - PIPK- 0000 /NIBD-0000/2020
- Interventions - Other: convalescent plasma
- Study type - Interventional
- Study results - No Results Available
- Locations - National Institute of Blood Diseases and Bone Marrow Transplantation (NIBD), Karachi, Sindh, Pakistan
- Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other
- Enrollment - 2000
- Age - 18 Years to 55 Years (Adult)
- Outcome measures - Change in COVID-19 severity status
|
NCT04973488
|
Therapeutic Plasma Exchange Followed by Convalescent Plasma Transfusion in Severe and Critically Ill COVID-19 Patients |
Completed |
Phase 2|Phase 3 |
Jul/25/2020 |
Jan/10/2021 |
- Alternative id - STUDYTPECVP20
- Interventions - Other: Therapeutic plasma exchange
- Study type - Interventional
- Study results - No Results Available
- Locations - Municipal Hospital "Dr. Teodor Andrei" Lugoj, Lugoj, Timis, Romania
- Study designs - Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 38
- Age - 18 Years to 90 Years (Adult, Older Adult)
- Outcome measures - Survival|Partial pressure of arterial oxygen (PaO2) to fractional inspired oxygen (FiO2) ratio (P/F ratio)|C reactive protein (CRP)|Lactate dehydrogenase (LDH)|Ferritin
|
NCT04421404
|
Effects of COVID-19 Convalescent Plasma (CCP) on Coronavirus-associated Complications in Hospitalized Patients |
Completed |
Phase 2 |
Jun/09/2020 |
Apr/30/2021 |
- Alternative id - 20-30794
- Interventions - Biological: COVID-19 Convalescent Plasma (CCP)|Biological: Placebo
- Study type - Interventional
- Study results - Has Results
- Locations - San Francisco General Hospital, San Francisco, California, United States|UCSF Medical Center at Mount Zion, San Francisco, California, United States|University of California, San Francisco Medical Center (Parnassus Campus), San Francisco, California, United States
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
- Enrollment - 34
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Mechanical Ventilation or Death Endpoint|8-Point Ordinal Scale Endpoint
|
NCT04407208
|
Convalescent Plasma Therapy in Patients With COVID-19 |
Completed |
Phase 1 |
May/01/2020 |
Jun/22/2020 |
- Alternative id - 3471041S322342020040800002
- Interventions - Biological: Convalescent plasma
- Study type - Interventional
- Study results - No Results Available
- Locations - Gatot Soebroto central army presidential hospital, Jakarta Pusat, Indonesia
- Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research
- Enrollment - 10
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Plaque reduction neutralization test (PNRT)|D-dimer|C-Reactive Protein (CRP)|International Normalized Ratio (INR)|Oxygenation Index|Chest X-ray|severe adverse event
|
NCT04332380
|
Convalescent Plasma for Patients With COVID-19: A Pilot Study |
Completed |
Phase 2 |
May/01/2020 |
Jul/28/2020 |
- Alternative id - ABN011-1
- Interventions - Drug: Plasma
- Study type - Interventional
- Study results - No Results Available
- Locations - Universidad del Rosario, Bogota, Cundinamarca, Colombia
- Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 10
- Age - 18 Years to 60 Years (Adult)
- Outcome measures - Change in Viral Load|Change in Immunoglobulin M COVID-19 antibodies Titers|Change in Immunoglobulin G COVID-19 antibodies Titers|Intensive Care Unit Admission|Length of Intensive Care Unit stay|Length of hospital stay (days)|Requirement of mechanical ventilation|Duration (days) of mechanical ventilation|Clinical status assessed according to the World Health Organization guideline|Mortality
|
NCT04425915
|
Efficacy of Convalescent Plasma Therapy in Patients With COVID-19 |
Completed |
Phase 3 |
Jun/14/2020 |
Dec/15/2020 |
- Alternative id - ILBS-COVID-04
- Interventions - Biological: Convalescent Plasma|Other: Standard of Care
- Study type - Interventional
- Study results - No Results Available
- Locations - Maulana Azad Medical College, New Delhi, Delhi, India|Institute of Liver & Biliary Sciences, New Delhi, Delhi, India|Rajiv Gandhi Super Speciality Hospital, New Delhi, Delhi, India
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 400
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Efficacy of convalescent plasma in severe COVID 19 patients in time to clinical improvement (Clinical improvement: Reduction of two points in ordinal scale or live discharge from the intensive care unit, whichever is earlier)|Proportion of patients in each category according to the ordinal scale|Duration of oxygen therapy in both groups|Duration of hospital stay in both groups|Proportion of patients on mechanical ventilation at day 7 in both groups|Mortality in both groups|Duration of Intensive Care Unit stay|Incidence of adverse effects in both groups|Presence of antibodies against SARS-CoV-2 in serum after plasma administration|Change in Cytokines in both groups|Change in acute phase reactants in both groups|Correlation of the titers in COVID-19 convalescent plasma donors with duration of illness, the severity of symptoms, duration of hospital stay, drugs used in therapy, duration between recovery, and donation.
|
NCT04521036
|
Convalescent Plasma for COVID-19 Patients (CPCP) |
Not yet recruiting |
Phase 1|Phase 2 |
Dec/01/2020 |
Oct/30/2021 |
- Alternative id - ISC.20.11.2
- Interventions - Biological: Convalescent Plasma as Therapy for Covid-19 patients
- Study type - Interventional
- Study results - No Results Available
- Locations - Vinmec Research Institute of Stem Cell and Gene Technology, Hanoi, Vietnam
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 44
- Age - 18 Years to 75 Years (Adult, Older Adult)
- Outcome measures - Change in mortality|Change in requirement for mechanical ventilation|Change in the duration of mechanical ventilation|Incidence of Treatment-Emergent Adverse Events
|
NCT04816942
|
Clinical Efficacy of Early Administration of Convalescent Plasma Among COVID-19 Cases in Egypt |
Completed |
Phase 3 |
Apr/23/2020 |
Oct/12/2020 |
- Alternative id - 10-2020/13
- Interventions - Biological: Convalescent Plasma
- Study type - Interventional
- Study results - No Results Available
- Locations - Ministry of Health, Cairo, Giza, Egypt
- Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 102
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - COVID-19 Cure rate
|
NCT04747158
|
COVID-19 Convalescent Plasma Therapy |
Completed |
Phase 2|Phase 3 |
Aug/10/2020 |
Jan/10/2021 |
- Alternative id - PINV20-388
- Interventions - Biological: Convalescent plasma
- Study type - Interventional
- Study results - No Results Available
- Locations - Facultad de Ciencias Médicas - Universidad Nacional de Asunción, Asunción, Paraguay
- Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 350
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Overall survival (30-day mortality)|Median length of hospital stay|Change in clinical status|Change in inflammatory marker: ferritin|Change in inflammatory marker: D dimer|Change in inflammatory marker: leukocytes|Serum Antibody Titers|Transfer to ICU|Transfusion related events
|
NCT04502472
|
Treatment of Severe Coronavirus Disease 2019 (COVID-19) With Convalescent Plasma |
Terminated |
Phase 2|Phase 3 |
Jun/06/2020 |
Sep/30/2020 |
- Alternative id - Inova COVID-19 CCP
- Interventions - Biological: Convalescent plasma transfusion
- Study type - Interventional
- Study results - Has Results
- Locations - Inova Fairfax Medical Campus, Falls Church, Virginia, United States
- Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 109
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Change is Clinical Status|Transfusion Related Events Due to Administration of CCP|Length of Hospital Stay|Mechanical Ventilation|Change in Mechanical Ventilation Status|Mortality
|
NCT04358783
|
Convalescent Plasma Compared to the Best Available Therapy for the Treatment of SARS-CoV-2 Pneumonia |
Completed |
Phase 2 |
Apr/27/2020 |
May/01/2021 |
- Alternative id - IF20-00002
- Interventions - Biological: Plasma|Other: Best Available Therapy
- Study type - Interventional
- Study results - No Results Available
- Locations - Hospital Universitario José E. Gonzalez, Monterrey, Nuevo Leon, Mexico
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
- Enrollment - 31
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Early all-cause mortality|Time in days for SARS-CoV-2 RT-PCR negatives|The serum anti-SARS-CoV-2 antibody titres|Detection of serum antibodies
|
NCT04333251
|
Study Testing Convalescent Plasma vs Best Supportive Care |
Not yet recruiting |
Phase 1 |
Apr/01/2020 |
Dec/31/2022 |
- Alternative id - 020-123
- Interventions - Biological: high-titer anti-Sars-CoV-2 plasma|Other: oxygen therapy
- Study type - Interventional
- Study results - No Results Available
- Locations -
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 115
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - reduction in oxygen and ventilation support
|
NCT04390178
|
Convalescent Plasma as Treatment for Acute Coronavirus Disease (COVID-19) |
Completed |
Phase 1|Phase 2 |
Apr/10/2020 |
Dec/31/2020 |
- Alternative id - CP1
- Interventions - Biological: SARS-CoV-2 convalescent plasma
- Study type - Interventional
- Study results - No Results Available
- Locations - Danderyd Hospital, Danderyd, Sweden
- Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 10
- Age - 18 Years to 80 Years (Adult, Older Adult)
- Outcome measures - Disease progression|Adverse events (AE)|Time ro resolution of fever and symptoms|Clearance of viraemia|Inflammatory parameter C-reactive protein (CRP)|Inflammatory parameter white blood cell count|Inflammatory parameter haemoglobin (Hb)|Inflammatory parameter Pro-calcitonin|Inflammatory parameter Creatine Kinase|Antibody response to SARS-CoV-2
|
NCT04377672
|
Human Convalescent Plasma for High Risk Children Exposed or Infected With SARS-CoV-2 (COVID-19) |
Completed |
Phase 1 |
May/28/2020 |
Dec/13/2021 |
- Alternative id - IRB00247557
- Interventions - Biological: Anti-SARS-CoV-2 Human Convalescent Plasma
- Study type - Interventional
- Study results - No Results Available
- Locations - Johns Hopkins Hospitals, Baltimore, Maryland, United States
- Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 14
- Age - 1 Month to 18 Years (Child, Adult)
- Outcome measures - Safety of treatment with high-titer anti-SARS-CoV-2 plasma as assessed by adverse events|Proportion of subjects with disease worsening event|Pharmacokinetics of anti-SARS-CoV-2 antibodies as defined by changes in antibody titers|Proportion of subjects with a natural antibody response to SARS-CoV-2 infection
|
NCT04567173
|
Convalescent Plasma as Adjunctive Therapy for Hospitalized Patients With COVID-19 |
Recruiting |
Phase 2|Phase 3 |
Sep/21/2020 |
Jun/30/2021 |
- Alternative id - PHRR200824-002868
- Interventions - Drug: Anti-SARS-CoV-2 convalescent plasma
- Study type - Interventional
- Study results - No Results Available
- Locations - UP Philippine General Hospital, Manila, Philippines
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 136
- Age - 19 Years and older (Adult, Older Adult)
- Outcome measures - Incidence of serious adverse events|Quick SOFA (qSOFA) score|Cardiopulmonary arrest|ICU mortality|ICU length of stay|Hospital mortality|Hospital length of stay|Dialysis-free days|Vasopressor-free days|ICU-free days|28-day mortality|Anti-SARS-CoV-2 antibody titers|SARS-CoV-2 RNA by RT-PCR
|
NCT04616976
|
COVID-19 With Convalescent Plasma |
Completed |
|
Jan/01/2020 |
Nov/01/2020 |
- Alternative id - COVID-19 convalescent plasma
- Interventions - Biological: convalescent plasma
- Study type - Observational
- Study results - No Results Available
- Locations - Zhongda Hospital, Southeast University, Nanjing, Jiangsu, China
- Study designs - Observational Model: Case-Control|Time Perspective: Retrospective
- Enrollment - 78
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - 28-day mortality|SARS-CoV-2 negative conversion rate
|
NCT04441424
|
Convalescent Plasma Therapy on Critically-ill Novel Coronavirus (COVID-19) Patients |
Completed |
Not Applicable |
Apr/03/2020 |
Jun/01/2020 |
- Alternative id - CPT-COVID-19
- Interventions - Biological: Convalescent plasma|Drug: Hydroxychloroquin with Azithromycin
- Study type - Interventional
- Study results - No Results Available
- Locations - Akarkh Healt hdirectorate, Baghdad, Iraq
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 49
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Death versus survival of treated patients|The length of stay in hospitals
|
NCT04381936
|
Randomised Evaluation of COVID-19 Therapy |
Recruiting |
Phase 2|Phase 3 |
Mar/19/2020 |
Nov/01/2032 |
- Alternative id - NDPHRECOVERY|2020-001113-21|ISRCTN50189673
- Interventions - Drug: Lopinavir-Ritonavir|Drug: Corticosteroid|Drug: Hydroxychloroquine|Drug: Azithromycin|Biological: Convalescent plasma|Drug: Tocilizumab|Biological: Immunoglobulin|Drug: Synthetic neutralising antibodies|Drug: Aspirin|Drug: Colchicine|Drug: Baricitinib|Drug: Anakinra|Drug: Dimethyl fumarate|Drug: High Dose Corticosteroid|Drug: Empagliflozin|Drug: Sotrovimab
- Study type - Interventional
- Study results - No Results Available
- Locations - Kumasi Center for Collaborative Research in Tropical Medicine KNUST, Kumasi, Ghana|Indian Council of Medical Research, Division of Epidemiology and Communicable Diseases, New Delhi, India|Eijkman Oxford Clinical Research Unit (EOCRU), Eijkman Institute for Molecular Biology, Jakarta, Indonesia|Clinical Trial Unit, Oxford University Clinical Research Unit-Nepal, Patan Academy of Health Sciences, Kathmandu, Nepal|Wits Health Consortium, Johannesburg, South Africa|RECOVERY Sri Lanka & Pakistan, National Intensive Care Surveillance - M.O.R.U, Colombo, Sri Lanka|Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom|Oxford University Clinical Research Unit, Centre for Tropical Medicine, Ho Chi Minh City, Vietnam
- Study designs - Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 50000
- Age - Child, Adult, Older Adult
- Outcome measures - All-cause mortality|Duration of hospital stay|Composite endpoint of death or need for mechanical ventilation or ECMO
|
NCT04434131
|
Treatment With Investigational Convalescent Plasma and Measure Antibody Levels in Patients Hospitalized With COVID-19 |
Recruiting |
Phase 2 |
Apr/28/2020 |
Apr/28/2025 |
- Alternative id - 20-227
- Interventions - Drug: Convalescent Plasma
- Study type - Interventional
- Study results - No Results Available
- Locations - University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States
- Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention
- Enrollment - 30
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Correlation between the NAb dose titer in the convalescent plasma and change or lack of change when comparing pre-treatment and day one NAb titers to inpatients with documented COIVD-19 infection|Rapid deterioration as evidenced by increase in ordinal or news score within 4 hours of transfusion|Number of participants with clearance of viral shedding of SARSCoV-2 in nasopharyngeal or nasal samples
|
NCT04513158
|
Convalescent Plasma in the Early Treatment of High-Risk Patients With SARS-CoV-2 (COVID-19) Infection |
Recruiting |
Phase 2 |
Aug/14/2020 |
Dec/31/2021 |
- Alternative id - 20-N0124
- Interventions - Biological: Convalescent Plasma
- Study type - Interventional
- Study results - No Results Available
- Locations - Norton Hospital, Louisville, Kentucky, United States|Norton Women's and Children's Hospital, Louisville, Kentucky, United States|Norton Audubon Hospital, Louisville, Kentucky, United States|Norton Brownsboro Hospital, Louisville, Kentucky, United States
- Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 100
- Age - 18 Years to 99 Years (Adult, Older Adult)
- Outcome measures - Determine the therapeutic efficacy (response rate) of convalescent plasma infusion in patients at high risk for mortality when infected by SARS-CoV-2 (COVID-19).|Determine the immunologic effects of convalescent plasma infusion|Absolute lymphocyte count (10*3/uL)|reatinine kinase (mg/dL)|C-reactive protein (mg/dl)|D-Dimer (ng/ml FEU)|Interleukin-6 (pg/ml)|Ferritin (ng/mL)
|
NCT04392232
|
A Study of COVID 19 Convalescent Plasma in High Risk Patients With COVID 19 Infection |
Completed |
Phase 2 |
May/05/2020 |
Sep/21/2021 |
- Alternative id - 20-045
- Interventions - Drug: Convalescent Plasma
- Study type - Interventional
- Study results - No Results Available
- Locations - Good Samaritan Hospital, Cincinnati, Ohio, United States|Bethesda North Hospital, Cincinnati, Ohio, United States
- Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 159
- Age - 16 Years and older (Child, Adult, Older Adult)
- Outcome measures - Survival Rate
|
NCT04432272
|
ANTIBODY-LEVEL BASED ANALYSIS OF COVID-19 CONVALESCENT SERUM (ABACCuS) |
Terminated |
Phase 2 |
Jul/16/2020 |
Nov/28/2020 |
- Alternative id - 2020-198
- Interventions - Biological: COVID-19 convalescent plasma
- Study type - Interventional
- Study results - Has Results
- Locations - William Beaumont Hospital, Royal Oak, Michigan, United States
- Study designs - Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 71
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Avoidance of Intubation at 28 Days (Group A)|Mortality (Group B)|Cardio-circulatory Arrest|Patient Outcome at 28 Days|Renal Failure|Liver Failure|Cytokine Storm|Respiratory Support|Vasopressor Medication Support|Length of ICU Length of Stay|Intensive Care Unit (ICU) Mortality|Hospital Length of Stay|Ventilator Free Days|Intubation Duration|Readmission|Serum Anti-SARS-CoV-2 IgG|SARS-CoV-2 RNA|Mortality (Group A)|Time From Transfusion to End of Ventilator Support (Group B)
|
NCT04497779
|
Analysis of Coronavirus Disease 19 (COVID-19) Convalescent Plasma |
Recruiting |
|
Jul/13/2020 |
Aug/21/2023 |
- Alternative id - 20204|NCI-2020-04000|P30CA033572|TGen
- Interventions - Procedure: Biospecimen Collection|Other: Diagnostic Laboratory Biomarker Analysis|Other: Electronic Health Record Review|Other: Questionnaire Administration
- Study type - Observational
- Study results - No Results Available
- Locations - City of Hope Medical Center, Duarte, California, United States
- Study designs - Observational Model: Cohort|Time Perspective: Prospective
- Enrollment - 800
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Convalescent plasma (CCP) units infused in coronavirus disease-2019 (COVID-19) patients|All-cause mortality|Donor antibody levels|Incidence of adverse events|CCP recipient outcomes
|
NCT04372979
|
Efficacy of Convalescent Plasma Therapy in the Early Care of COVID-19 Patients. |
Recruiting |
Phase 3 |
Sep/14/2020 |
Jun/01/2021 |
- Alternative id - 2020-A01166-33
- Interventions - Drug: Transfusion of SARS-CoV-2 Convalescent Plasma.|Drug: Transfusion of standard Plasma.
- Study type - Interventional
- Study results - No Results Available
- Locations - HIA Percy, Clamart, France|HIA Laveran, Marseille, France|HIA Bégin, Saint-Mandé, France|HIA Sainte Anne, Toulon, France
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
- Enrollment - 80
- Age - 18 Years to 90 Years (Adult, Older Adult)
- Outcome measures - Survival time without needs of a ventilator.|Morbidity|Mortality|Length of stay|Effect on viral pharyngeal specimen clearance|Effect on viral blood specimen clearance|Effect on hemostasis disorders|Kinetics of appearance of neutralizing antibodies|Transfusion endotheliopathy effect|Transfusion biological Inflammation effect|Transfusion hemovigilance|Decrease in the consumption of antibiotics
|
NCT04343755
|
Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection |
Active, not recruiting |
Phase 2 |
Apr/09/2020 |
Apr/01/2022 |
- Alternative id - Pro2020-0375
- Interventions - Biological: Convalescent Plasma
- Study type - Interventional
- Study results - No Results Available
- Locations - Hackensack University Medical Center, Hackensack, New Jersey, United States
- Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 52
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - For patients hospitalized for COVID-19 but not intubated|Primary objective for patients with COVID-19 already intubated|Duration of hospitalization|Duration of mechanical ventilation|Time to symptoms resolution|Overall survival|Rate of virologic clearance by nasopharyngeal swab at day 10|Impact of donor titers level on efficacy|Impact of donor titers level on safety|Recipient Anti-SARS-CoV2 titer assessment on days 0 (pre-infusion),3,10,30, 60
|
NCT04340050
|
COVID-19 Convalescent Plasma |
Completed |
Early Phase 1 |
Apr/10/2020 |
Dec/23/2020 |
- Alternative id - IRB20-0523
- Interventions - Biological: anti-SARS-CoV-2 convalescent plasma
- Study type - Interventional
- Study results - No Results Available
- Locations - University of Chicago Medicine, Chicago, Illinois, United States
- Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 10
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Feasibility of performing study pathway consisting of consenting convalescent donors, harvesting convalescent plasma, application for FDA eIND and administering convalescent plasma to the patients|Type of respiratory support|Cardiac arrest|Transfer to ICU|ICU mortality|ICU length of stay|Hospital mortality|Hospital length of stay|Ventilator-free days|Overall survival (28-day mortality)
|
NCT04374526
|
Early transfusIon of Convalescent Plasma in Elderly COVID-19 Patients. to Prevent Disease Progression. |
Completed |
Phase 2|Phase 3 |
May/27/2020 |
May/26/2021 |
- Alternative id - 3205
- Interventions - Biological: COVID-19 Convalescent Plasma
- Study type - Interventional
- Study results - No Results Available
- Locations - Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, RM, Italy|Ospedale SS Annunziata, Chieti, Italy|Istituto Nazionale Malattie Infettive Lazzaro Spallanzani, Rome, Italy
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention
- Enrollment - 29
- Age - 65 Years and older (Older Adult)
- Outcome measures - Rate of COVID-19 progression
|
NCT04458363
|
Convalescent Plasma in Pediatric COVID-19 |
Completed |
Early Phase 1 |
Jul/04/2020 |
Sep/01/2020 |
- Alternative id - STUDY00000789
- Interventions - Biological: Convalescent Plasma (CP)|Drug: Standard COVID-19 therapies
- Study type - Interventional
- Study results - No Results Available
- Locations - Children's Healthcare of Atlanta, Atlanta, Georgia, United States
- Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 3
- Age - up to 22 Years (Child, Adult)
- Outcome measures - Number of grade 3-5 adverse events that are possible, probably or definitely related to the convalescent plasma (CP) infusion|Change in percent of supplemental oxygen|Number of patients that required change in level of respiratory support|Mortality|Mean length of ICU stay (days)|Mean length of hospital stay (days)|Mean length of ventilation (days)|Number of patients with progression to renal dysfunction and/or multisystem organ failure|IL-6 level|Number of anti-SARS CoV 2 specific T cells|Diversity of circulating T cells|ARS-CoV-2 Antibody Titer|SARS-CoV-2 Neutralizing Titer
|
NCT05271929
|
Early High-Titre Convalescent Plasma in Clinically Vulnerable Individuals With Mild COVID-19 |
Not yet recruiting |
Phase 3 |
Mar/10/2022 |
Sep/10/2024 |
- Alternative id - COVIC-19
- Interventions - Biological: COVID-19 convalescent and vaccinated plasma|Other: Current standard of care
- Study type - Interventional
- Study results - No Results Available
- Locations - CHU Besançon, Besançon, France|Klinikum Stuttgart, Stuttgart, Baden-Wuertemberg, Germany|Diakonie-Klinikum Stuttgart, Stuttgart, Baden-Wuertemberg, Germany|Uniklinikum Tübingen, Tübingen, Baden-Wuertemberg, Germany|Institut für Klinische Transfusionsmedizin (IKT), Ulm, Baden-Wuertemberg, Germany|Uniklinikum Ulm, Ulm, Baden-Wuertemberg, Germany|Universitätsklinikum Brandenburg, Brandenburg an der Havel, Brandenburg, Germany|Elblandkliniken Riesa, Riesa, Sachsen, Germany|Charité Medizinische Klinik IV, Berlin, Germany|NHS Blood and Transplant, Oxford, United Kingdom
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 680
- Age - Child, Adult, Older Adult
- Outcome measures - Proportion of participants with hospitalisation with O2 support or death|Proportion of participants with hospitalisation for progressive COVID-19 symptoms requiring O2 support, or death|Proportion of patients with hospitalisation and/or additional treatment for COVID-19|All-cause mortality|Proportion of patients with supplemental oxygen|Proportion of patients with non-invasive ventilation|Proportion of patients with intubation and mechanical ventilation|Change in 10-point WHO Clinical Progression Scale score|Duration of hospital admission censored at 28 days|Proportion of patients with admission to ITU|Duration of ITU admission censored at 28 days|Proportion of patients with long COVID-19 symptoms|Health-related quality of life assessed by EQ-5D quality of life index|Number of Serious Adverse Events|Number of Participants with arterial and venous thromboembolic events
|
NCT04570982
|
Clinical Protocol for Convalescent Plasma and Remdesivir Therapy in Nepal |
Recruiting |
|
Jul/30/2020 |
Dec/30/2020 |
- Alternative id - NHRC2020-001
- Interventions - Biological: Convalescent Plasma
- Study type - Observational
- Study results - No Results Available
- Locations - Narayani Hospital, Birgunj, Nepal|Seti Provincial Hospital, Dhangadi, Nepal|BP Koirala Institute of Health Sciences (BPKIHS), Dharān Bāzār, Nepal|Sukraraj Tropical Disease Hospital, Kathmandu, Nepal|TU Teaching Hospital, Kathmandu, Nepal|Bheri Provincial Hospital, Nepalgunj, Nepal
- Study designs - Observational Model: Case-Crossover|Time Perspective: Prospective
- Enrollment - 200
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Availability of convalescent plasma|Amount of Plasma|Demographics of recipients|Co-morbidity of recipient|Donor status|Adverse events of convalescent COVID-19 plasma and Remdesivir Therapy|Hospital and ICU length of stay|Disposition of patients including survival
|
NCT04497324
|
PERUCONPLASMA: Evaluating the Use of Convalescent Plasma as Management of COVID-19 |
Completed |
Phase 2 |
Sep/21/2020 |
Apr/17/2021 |
- Alternative id - PER-016-20|20997
- Interventions - Biological: Convalescent plasma
- Study type - Interventional
- Study results - No Results Available
- Locations - Hospital Cayetano Heredia, Lima, Peru|Hospital Nacional Hipolito Unanue, Lima, Peru
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 100
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Transfusion-related Serious Adverse Events|All-cause in-hospital mortality|Length of hospital stay|Length of ICU stay|Need of invasive mechanical ventilation|Duration of mechanical ventilation|Clinical Improvement at 14 days
|
NCT04333355
|
Safety in Convalescent Plasma Transfusion to COVID-19 |
Terminated |
Phase 1 |
May/08/2020 |
Aug/20/2020 |
- Alternative id - PC-TecSalud Fase I
- Interventions - Biological: Convalescent Plasma
- Study type - Interventional
- Study results - No Results Available
- Locations - Hospital San José, Monterrey, Nuevo Leon, Mexico
- Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 12
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Side effects|Heart Failure|Pulmonary Edema|Allergic Reaction|Viral load of SARS-CoV-2
|
NCT04516954
|
Convalescent Plasma for COVID-19 Patients |
Enrolling by invitation |
Early Phase 1 |
Aug/01/2020 |
Dec/30/2020 |
- Alternative id - ISC.20.11.1
- Interventions - Biological: Convalescent COVID 19 Plasma
- Study type - Interventional
- Study results - No Results Available
- Locations - Vinmec Research Institute of Stem cell and Gene Technology, Hanoi, Vietnam
- Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 10
- Age - 18 Years to 75 Years (Adult, Older Adult)
- Outcome measures - Evaluate the safety|Change in requirement for mechanical ventilatory support
|
NCT04385186
|
Inactivated Convalescent Plasma as a Therapeutic Alternative in Patients CoViD-19 |
Not yet recruiting |
Phase 2 |
Jun/20/2020 |
Dec/30/2020 |
- Alternative id - CT01
- Interventions - Drug: Inactivated convalescent plasma|Drug: Support treatment
- Study type - Interventional
- Study results - No Results Available
- Locations - Clínica Antioquía, Medellín, Antioquía, Colombia|Clínica Sagrado Corazón, Medellín, Antioquía, Colombia|IPS Universitaria, Medellín, Antioquía, Colombia|Universidad de Antioquía, Medellín, Antioquía, Colombia|National Blood Center Foundation, Hemolife/Fundación Banco Nacional de Sangre Hemolife, Bogotá, Cundinamarca, Colombia|Clínica Rosales, Pereira, Risaralda, Colombia|Clinica Nuestra, Cali, Valle, Colombia|Clínica Corpas, Bogotá, Colombia|E.S.E Hospital San Rafael Facatativa, Facatativa, Colombia|Clínica la Estancia, Popayán, Colombia
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment
- Enrollment - 60
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Mortality reduction in CoViD-19 patients treated with inactivated convalescent plasma + support treatment|Clinical evolution|Clinical evolution by seven-parameter ordinal scale|Multi-organ failure progression|Change in hemoglobin concentration|Change in blood cell count|Change in serum creatinine level|Change in aspartate aminotransferase level|Change in alanin aminotransferase level|Change in bilirubin level|Change in lactate dehydrogenase level|Change in creatine kinase level|Change in creatine kinase MB level|Change in C reactive protein concentration|Change in D Dimer concentration|Change in Procalcitonin concentration|Change in IL6 level|Radiography imaging|Tomography imaging|Assessment of oxygenation|Viral Load|Antibody titer|Oxygen-free days through Day 60|Mechanical ventilation-free days through Day 28|Intensive Care Unit (ICU)-free days through Day 28|Hospital-free days through Day 60
|
NCT04425837
|
Effectiveness and Safety of Convalescent Plasma in Patients With High-risk COVID-19 |
Not yet recruiting |
Phase 2|Phase 3 |
Jul/01/2020 |
Feb/01/2021 |
- Alternative id - PLASMA COVID-19
- Interventions - Biological: SARS-CoV-2 convalescent plasma treatment|Other: Standard care
- Study type - Interventional
- Study results - No Results Available
- Locations - Fundación Santa Fe de Bogotá, Bogotá, Cundinamarca, Colombia
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment
- Enrollment - 236
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Mortality|Adverse events|ICU admission|Mechanical ventilation|ICU length|Reduction of D Dimer|LDH reduction|Reduction of Troponin level|Decrease in ferritin level|Decrease in procalcitonin level|Decrease in CRP|Increase in lymphocyte count|Increase in PaO2 / Fio2|Decrease in Sequential Organ failure assessment (SOFA ) score|Extracorporeal membrane oxygenation (ECMO)|Lung infiltration
|
NCT04415086
|
Treatment of Patients With COVID-19 With Convalescent Plasma |
Active, not recruiting |
Phase 2 |
Jun/01/2020 |
May/22/2022 |
- Alternative id - COOP-COVID-19-MCTIC
- Interventions - Biological: convalescent plasma
- Study type - Interventional
- Study results - No Results Available
- Locations - University of Sao Paulo - General Hospital, São Paulo, SP, Brazil
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 129
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Time elapsed until clinical improvement or hospital discharge|acute adverse events|Clinical Status|Duration of clinical events|SARS-CoV-2 in nasopharyngeal swab|IgG, IgM and IgA titers for SARS-CoV-2|Neutralizing antibodies
|
NCT04342182
|
Convalescent Plasma as Therapy for Covid-19 Severe SARS-CoV-2 Disease (CONCOVID Study) |
Active, not recruiting |
Phase 2|Phase 3 |
Apr/08/2020 |
Jul/31/2021 |
- Alternative id - NL73489.078.20
- Interventions - Biological: Convalescent plasma
- Study type - Interventional
- Study results - No Results Available
- Locations - Erasmus Medical Center, Rotterdam, Zuid-Holland, Netherlands|NoordWest Ziekenhuisgroep, Alkmaar, Netherlands|Onze Lieve Vrouwen Gasthuis, Amsterdam, Netherlands|Rijnstate Ziekenhuis, Arnhem, Netherlands|Reinier de Graaf Gasthuis, Delft, Netherlands|Haaglanden Medisch Centrum, Den Haag, Netherlands|Catharina Ziekenhuis, Eindhoven, Netherlands|Medisch Spectrum Twente, Enschede, Netherlands|Groene Hart Ziekenhuis, Gouda, Netherlands|Martini Hospital, Groningen, Netherlands|Spaarna Gasthuis, Haarlem, Netherlands|Alrijne Ziekenhuis, Leiderdorp, Netherlands|Sint Antonius Ziekenhuis, Nieuwegein, Netherlands|Canisius-Wilhelmina Hospital, Nijmegen, Netherlands|Maasstad Ziekenhuis, Rotterdam, Netherlands|ZorgSaam Hospital, Terneuzen, Netherlands|Bernhoven Hospital, Uden, Netherlands|VieCuri, Venlo, Netherlands
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 426
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Overall mortality until discharge from the hospital or a maximum of 60 days after admission whichever comes first|Impact of 300ml convP therapy on hospital days|Impact of 300ml convP on weaning from oxygen therapy|Impact of 300ml convP on overall mortality in patients admitted to the ICU within 24 hours after admission|Difference in the effect of convP on mortality in patients with a duration of symptoms less or more the median duration of symptoms in the study population|Impact of 300ml convP therapy on ICU days in patients admitted to the ICU within 24 hours after admission|Impact of plasma therapy on the decrease in SARS-CoV2 shedding from airways|Impact of CTL and NK cell immunity on the likelihood of being protected from immune serum transfer|Safety of convP therapy|Change of the 8-point WHO COVID19 disease severity scale on day 15|Change of the 8-point WHO COVID19 disease severity scale on day 30|Change of the 8-point WHO COVID19 disease severity scale on day 15 in the subgroup of patients with a baseline neutralizing antibody titer (PRNT50) <80.|Impact of plasma therapy on risk of long-term structural lung damage and lung function
|
NCT04345523
|
Convalescent Plasma Therapy vs. SOC for the Treatment of COVID-19 in Hospitalized Patients |
Completed |
Phase 2 |
Apr/03/2020 |
Apr/05/2021 |
- Alternative id - ConPlas-19
- Interventions - Other: Blood and derivatives.|Drug: Standard of Care
- Study type - Interventional
- Study results - No Results Available
- Locations - Hospital Clínico Universitario Lozano Blesa, Zaragoza, Aragón, Spain|Hospital Universitario Mútua Terrassa, Terrassa, Barcelona, Spain|Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Madrid, Spain|Hospital General de Albacete, Albacete, Spain|Hospital del Mar, Barcelona, Spain|Hospital General Universitario de Ciudad Real, Ciudad Real, Spain|Hospital Universitario Donostia, Donostia, Spain|Hospital Doctor Josep Trueta, Girona, Spain|Hospital Doctor Negrín, Las Palmas, Spain|Complejo Asistencial Universitario de León, León, Spain|Hospital Universitario Arnau de Vilanova, Lleida, Spain|Hospital San Pedro, Logroño, Spain|Hospital Universitario La Princesa, Madrid, Spain|Hospital General Universitario Gregorio Marañón, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario HM Sanchinarro, Madrid, Spain|Hospital Sant Joan de Deu de Manresa. Fundación Althaia, Manresa, Spain|Hospital Universitario de Asturias, Oviedo, Spain|Hospital Universitario Son Espases, Palma De Mallorca, Spain|Clínica Universidad de Navarra (CUN). Sedes Pamplona y Madrid, Pamplona, Spain|Complejo Hospitalario de Navarra, Pamplona, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Marqués de Valdecilla, Santander, Spain|Complejo Hospitalario de Toledo, Toledo, Spain|Hospital General Universitario de Valencia, Valencia, Spain|Hospital Clínico Universitario de Valladolid, Valladolid, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 350
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Category Changes in the "7-Ordinal Scale"|Time to category 5, 6 or 7 of the " 7-Ordinal scale"|Time to an improvement of one category from admission in the "7-Ordinal scale"|Status at day 30 in the "11-Ordinal scale"|Status at day 15 and 30 in the "11-Ordinal scale"|Time to first deterioration|Mean change in the ranking in the "7-Ordinal scale" from baseline to days 3,5,8,11,15,29 and 60|Mean change in the ranking in the "11-Ordinal scale from baseline to days 3,5,8,11,15,29 and 60.|Mortality of any cause at 15 days|Mortality of any cause at 28 days (day 29)|Mortality of any cause at 60 days|Oxygenation free days|Ventilator free days|Duration of hospitalization (days)|Infusion-related adverse events|Incidence of Treatment-Emergent Adverse Events|Antibodies levels in CP donors recovered from COVID-19|Viral load|Incidence of thrombotic arterial events|Incidence of thrombotic venous events|rate of rehospitalizations
|
NCT04954937
|
Convalescent Plasma Donor Vaccine Study An Observational Antibody Level Study. |
Recruiting |
|
Apr/20/2021 |
Apr/20/2022 |
- Alternative id - 21AS0001
- Interventions -
- Study type - Observational
- Study results - No Results Available
- Locations - NHSBT - Birmingham Donation Centre, Birmingham, United Kingdom
- Study designs - Observational Model: Other|Time Perspective: Prospective
- Enrollment - 100
- Age - 17 Years to 66 Years (Child, Adult, Older Adult)
- Outcome measures - Increase in antibody levels post-vaccination assessed via Euroimmun assay|Increase in antibody levels post-vaccination assessed via Roche IgG assay|Increase in antibody levels post-vaccination assessed vial live virus neutralization
|
NCT04389710
|
Convalescent Plasma for the Treatment of COVID-19 |
Completed |
Phase 2 |
Apr/15/2020 |
Dec/07/2020 |
- Alternative id - 20D.379
- Interventions - Drug: Convalescent Plasma
- Study type - Interventional
- Study results - No Results Available
- Locations - Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
- Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 52
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Number of patients who receive COVID-19 convalescent plasma transfusions in acute care facilities infected with SARS-CoV-2|Number and type of adverse events associated with COVID-19 convalescent plasma in patients with COVID-19|Length of hospital stay|Length of Intensive Care Unit stay|Length of intubation|Survival to discharge|Changes in complete blood count in patients after receiving convalescent plasma|Abnormal changes in Basic Metabolic Panel (BMP) measures in patients after receiving convalescent plasma|Changes in C-Reactive Protein (CRP) in patients after receiving convalescent plasma|Changes in d-dimer in patients after receiving convalescent plasma|Changes in fibrinogen in patients after receiving convalescent plasma|Changes in prothrombin time (PT) in patients after receiving convalescent plasma|Changes in partial thromboplastin time (PTT) in patients after receiving convalescent plasma
|
NCT04462848
|
Covid-19 Convalescent Plasma as Prevention and Treatment for Children With Underlying Medical Conditions |
Not yet recruiting |
Phase 1 |
Aug/01/2020 |
Dec/01/2024 |
- Alternative id - IRB#20-001263
- Interventions - Biological: anti-SARS-CoV-2 human convalescent plasma
- Study type - Interventional
- Study results - No Results Available
- Locations - University of California, Los Angeles (UCLA), Los Angeles, California, United States
- Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 30
- Age - 1 Month to 17 Years (Child)
- Outcome measures - Cumulative incidence of Grade 3 and Grade 4 adverse events|Cumulative incidence of serious adverse events|Proportion of participants with disease worsening event.|Serum concentration at baseline, Day 7, Day 14, and Day 28 for anti-SARS-CoV-2 antibodies|Percentage of participants with a natural antibody response to SARS-CoV-2 infection
|
NCT04471051
|
An Observational Cohort Trial of Outcomes and Antibody Responses Following Treatment With COVID19 Convalescent Plasma in Hospitalized COVID-19 Patients |
Completed |
|
Apr/30/2020 |
Aug/20/2020 |
- Alternative id - 20-0986
- Interventions -
- Study type - Observational
- Study results - No Results Available
- Locations - Children's Hospital Colorado, Aurora, Colorado, United States|University of Colorado Hospital, Aurora, Colorado, United States|UCHealth Memorial Hospital North, Colorado Springs, Colorado, United States|Denver Health Medical Center, Denver, Colorado, United States|UCHealth Poudre Valley Hospital, Fort Collins, Colorado, United States|UCHealth Highlands Ranch Hospital, Highlands Ranch, Colorado, United States
- Study designs - Observational Model: Cohort|Time Perspective: Prospective
- Enrollment - 255
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Inpatient Mortality|Requirement for mechanical ventilation|Transfer to ICU|ICU Mortality|ICU Length of Stay (LOS)|Hospital Mortality|Hospital Length of Stay (LOS)
|
NCT04412486
|
COVID-19 Convalescent Plasma (CCP) Transfusion |
Recruiting |
Early Phase 1 |
Jun/01/2020 |
May/31/2022 |
- Alternative id - 2020-0137
- Interventions - Biological: COVID Convalescent Plasma
- Study type - Interventional
- Study results - No Results Available
- Locations - University of Mississippi Medical Center, Jackson, Mississippi, United States
- Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 100
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Change in PaO2/FiO2 after CCP transfusion.|Change in pulse oximetry status after CCP transfusion.|Change in aO2 after CCP transfusion.|Change in respiratory rate after CCP transfusion.|Change in intubation status after CCP transfusion.|Change in Sequential Organ Failure Assessment (SOFA).|Change in 8-point ordinal clinical deterioration scale.|Length of ICU/hospital stay.|Development of plasma transfusion reactions.|Development of immune complex disorders.|Change in anti CoV-2 IgM and IgG levels.
|
NCT04385199
|
Convalescent Plasma for Patients With COVID-19 |
Completed |
Phase 2 |
May/04/2020 |
Aug/01/2020 |
- Alternative id - 13807
- Interventions - Biological: Convalescent plasma
- Study type - Interventional
- Study results - No Results Available
- Locations - Henry Ford Hospital, Detroit, Michigan, United States
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 30
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Improvement in respiratory disease|ICU Length of Stay|Length of Stay|Ventilator days|Tolerability of convalescent plasma|Radiographic improvement
|
NCT04730401
|
Convalescent Plasma in the Treatment of Covid-19 |
Recruiting |
Phase 2 |
Jan/27/2021 |
Dec/31/2021 |
- Alternative id - Plasma_Covid-19
- Interventions - Biological: Convalescent plasma from COVID-19 donors|Biological: Placebo
- Study type - Interventional
- Study results - No Results Available
- Locations - Helsinki University Central Hospital, Helsinki, Uusimaa, Finland
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
- Enrollment - 390
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Safety (SAE)|Rate of intubation|Number of participants initiating systemic corticosteroids|Hospital stay|Mortality|ICU stay|Ventilator days|Severity of respiratory failure|Viral load|Antibody measurements|Thrombotic complication|The rate of participants presenting with coagulopathy disorders|Number of participants with laboratory change|Adverse effects|Convalescent plasma efficacy|Convalescent plasma high vs low titer efficacy|Convalescent plasma efficacy according to donor status
|
NCT04389944
|
Amotosalen-Ultraviolet A Pathogen-Inactivated Convalescent Plasma in Addition to Best Supportive Care and Antiviral Therapy on Clinical Deterioration in Adults Presenting With Moderate to Severe COVID-19 |
Completed |
Not Applicable |
Mar/31/2020 |
Jun/30/2020 |
- Alternative id - Req-2020-00508; me20khanna2
- Interventions - Other: convalescent plasma application to SARS-CoV-2 infected patients
- Study type - Interventional
- Study results - No Results Available
- Locations - Blutspendezentrum SRK beider Basel, University Hospital Basel, Basel, Switzerland
- Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 15
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Serious adverse events in convalescent plasma treated patients|Virologic clearance in nasopharyngeal swab of convalescent plasma treated patients|Transfer to ICU|in-hospital death|Virologic clearance in plasma of convalescent plasma treated patients|Time to discharge from hospital after enrolment|Humoral immune response
|
NCT04374565
|
Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia |
Active, not recruiting |
Phase 2 |
May/05/2020 |
Apr/05/2021 |
- Alternative id - 200114
- Interventions - Drug: High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma
- Study type - Interventional
- Study results - No Results Available
- Locations - University of Virginia Medical Center, Charlottesville, Virginia, United States|University of Virginia, Charlottesville, Virginia, United States
- Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 29
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Transfer to ICU|28 day mortality|Cumulative incidence of serious adverse events|Rates and duration of SARS-CoV-2|Serum of plasma antibody titer to SARS-CoV-2|Cellular and humoral immune response|Supplemental oxygen free days|Ventilator free days|ICU free days|Sequential organ failure assessment score|Need for vasopressors|Need for renal replacement therapy|Need for extracorporeal membrane oxygenation (ECMO)|Hospital length of stay (LOS)|ICU LOS|Grade 3 or 4 Adverse Events (AEs)
|
NCT04365439
|
Convalescent Plasma for COVID-19 |
Active, not recruiting |
Not Applicable |
Jul/20/2020 |
Jun/30/2021 |
- Alternative id - 2020-00895
- Interventions - Biological: Blood plasma
- Study type - Interventional
- Study results - No Results Available
- Locations - Ospedale Regionale Locarno, Locarno, Ticino, Switzerland
- Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 11
- Age - 18 Years to 75 Years (Adult, Older Adult)
- Outcome measures - Titers of anti-SARS-CoV-2 antibodies in the plasma derived from convalescent donors|Change in titers of anti-SARS-CoV-2 antibodies in patients' plasma|Change in inflammatory cytokines concentration (e.g. IL-6, HMGB1)|Viral load decay in the recipient after plasma transfusion with semiquantitative assessment of nasopharyngeal swabs|Number of patients with improvement in the 7-points Ordinal Scale|Proportion of patients with adverse events, severity of adverse events
|
NCT04391101
|
Convalescent Plasma for the Treatment of Severe SARS-CoV-2 (COVID-19) |
Not yet recruiting |
Phase 3 |
Jun/01/2020 |
Dec/01/2021 |
- Alternative id - 002
- Interventions - Drug: Convalescent plasma
- Study type - Interventional
- Study results - No Results Available
- Locations - Hospital San Vicente Fundacion, Medellín, Antioquia, Colombia
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 231
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Intrahospital mortality from any cause|Length of hospital stay|Free time for ventilatory support on day 60|Overall survival at day 60 since hospitalization|Cumulative incidence of adverse events: transfusion reactions (fever, flare), TRALI (transfusion-associated lung injury), TACO (transfusion-related circulatory overload), transfusion- related infections
|
NCT04460547
|
Worldwide Trends on COVID-19 Research After the Declaration of COVID-19 Pandemic |
Not yet recruiting |
|
Jul/25/2020 |
Sep/20/2020 |
- Alternative id - COAHS
- Interventions - Drug: Convalescent Plasma Transfusion|Drug: Hydroxychloroquine|Drug: DAS181|Drug: Ivermectin|Drug: Interferon Beta-1A
- Study type - Observational
- Study results - No Results Available
- Locations -
- Study designs - Observational Model: Cohort|Time Perspective: Retrospective
- Enrollment - 200
- Age - 1 Year and older (Child, Adult, Older Adult)
- Outcome measures - Geographical distribution of the interventional studies after 11th of March 2020.|Geographical distribution of the Observational studies after 11th of March 2020.|Monthly Research study completion rate as per geographic distribution of the Research.|Statistical correlation of the interventional studies Research with developed, developing and under developed countries.|Statistical correlation of the observational studies Research with developed, developing and under developed countries.|Statistical correlation of the Drug based interventional studies Research with developed, developing and under developed countries.|Statistical correlation of the Diagnostic test based interventional studies Research with developed, developing and under developed countries.|Statistical correlation of the Device based interventional studies Research with developed, developing and under developed countries.
|
NCT04372368
|
Convalescent Plasma for the Treatment of Patients With COVID-19 |
No longer available |
|
Jan/01/1970 |
Jan/01/1970 |
- Alternative id - 20-0990
- Interventions - Biological: COVID-19 Convalescent Plasma
- Study type - Expanded Access:Treatment IND/Protocol
- Study results - No Results Available
- Locations - Children's Hospital Colorado, Aurora, Colorado, United States|University of Colorado Hospital, Aurora, Colorado, United States|UCHealth Memorial Hospital North, Colorado Springs, Colorado, United States|Denver Health Medical Center, Denver, Colorado, United States|UCHealth Poudre Valley Hospital, Fort Collins, Colorado, United States|UCHealth Highlands Ranch Hospital, Highlands Ranch, Colorado, United States
- Study designs -
- Enrollment -
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures -
|
NCT04395170
|
Convalescent Plasma (PC) and Human Intravenous Anti-COVID-19 Immunoglobulin (IV Anti COVID-19 IgG) in Patients Hospitalized for COVID-19. |
Not yet recruiting |
Phase 2|Phase 3 |
Sep/01/2020 |
Jun/01/2021 |
- Alternative id - LFCOLCOVID-19-001
- Interventions - Biological: COVID-19 convalescent plasma|Biological: Anti-COVID-19 human immunoglobulin|Drug: Standard (specific) therapy for COVID-19
- Study type - Interventional
- Study results - No Results Available
- Locations - LifeFactors Zona Franca SAS, Medellín, Antioquia, Colombia
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 75
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Admission to ICU and/or mechanical ventilation|Length of hospital stay|Neutralizing antibody (IgG) titers against COVID-19|Safety - Adverse events|Death
|
NCT04383548
|
Clinical Study for Efficacy of Anti-Corona VS2 Immunoglobulins Prepared From COVID19 Convalescent Plasma Prepared by VIPS Mini-Pool IVIG Medical Devices in Prevention of SARS-CoV-2 Infection in High Risk Groups as Well as Treatment of Early Cases of COVID19 Patients |
Not yet recruiting |
Not Applicable |
Jun/01/2020 |
Jan/01/2021 |
- Alternative id - Mini-pooled IVIG in COVID19
- Interventions - Other: hyper immunoglobulins containing anti-Corona VS2 immunoglobulin
- Study type - Interventional
- Study results - No Results Available
- Locations -
- Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 100
- Age - 21 Years to 50 Years (Adult)
- Outcome measures - Efficacy of COVID19 hyper immunoglobulins for patients|Efficacy of COVID19 hyper immunoglobulins for high risk groups|Safety of anti-SARS-CoV-2 hyper immunoglobulins assessed by percentage of adverse events
|
NCT04360486
|
Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP) |
No longer available |
|
Jan/01/1970 |
Jan/01/1970 |
- Alternative id - S-20-02|IND 19930
- Interventions - Biological: Anti-Sars-CoV-2 Convalescent Plasma
- Study type - Expanded Access:Treatment IND/Protocol
- Study results - No Results Available
- Locations - Naval Hospital Camp Pendleton, Oceanside, California, United States|Navy Medical Center San Diego, San Diego, California, United States|USS Abraham Lincoln, San Diego, California, United States|USS Carl Vinson, San Diego, California, United States|USS Essex, San Diego, California, United States|USS Makin Island, San Diego, California, United States|USS Nimitz, San Diego, California, United States|USS Theodore Roosevelt, San Diego, California, United States|Evans Army Community Hospital, Fort Carson, Colorado, United States|Eglin Air Force Base, Eglin Air Force Base, Florida, United States|Naval Hospital Jacksonville, Jacksonville, Florida, United States|Martin Army Community Hospital, Fort Benning, Georgia, United States|Eisenhower Army Medical Center, Fort Gordon, Georgia, United States|Tripler Army Medical Center, Honolulu, Hawaii, United States|Keesler Medical Center, Biloxi, Mississippi, United States|Nellis Air Force Base, Las Vegas, Nevada, United States|Naval Medical Center Camp Lejeune, Camp Lejeune, North Carolina, United States|Wright Patterson Medical Center, Wright-Patterson Air Force Base, Ohio, United States|William Beaumont Army Medical Center, El Paso, Texas, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States|Fort Belvoir Community Hospital, Fort Belvoir, Virginia, United States|Naval Surface Force Atlantic, Norfolk, Virginia, United States|USS Dwight D. Eisenhower, Norfolk, Virginia, United States|USS Gerald R. Ford, Norfolk, Virginia, United States|Naval Medical Center Portsmouth, Portsmouth, Virginia, United States|Madigan Army Medical Center, Lakewood, Washington, United States|Craig Joint Theatre Hospital Bagram AFGH, Bagram, Afghanistan|Djibouti Expeditionary Medical Facility, Djibouti, Djibouti|Landstuhl Regional Medical Center, Landstuhl, Germany|Naval Hospital Guam, Agaña, Guam|Baghdad Diplomat Support Center Iraq, Baghdad, Iraq|Misawa Air Force Base, Aomori, Japan|Yokota Air Base, Fussa, Japan|US Naval Hospital Okinawa, Okinawa, Japan|Naval Hospital Yokosuka, Yokosuka, Japan|USS America, Yokosuka, Japan|USS Ronald Reagan, Yokosuka, Japan|US Military Hospital Kuwait, Kuwait, Kuwait
- Study designs -
- Enrollment -
- Age - Child, Adult, Older Adult
- Outcome measures -
|
NCT04390503
|
Convalescent Plasma for Early Treatment of COVID-19 |
Recruiting |
Phase 2 |
Mar/12/2021 |
Apr/01/2022 |
- Alternative id - AAAT0052
- Interventions - Biological: Convalescent Plasma (anti-SARS-CoV-2 plasma)|Biological: Control (albumin 5%)
- Study type - Interventional
- Study results - No Results Available
- Locations - National Institute of Infectious Diseases Evandro Chagas (INI), Rio de Janeiro, Brazil
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment
- Enrollment - 150
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Rate of Severe Disease|Rate of measurable anti-SARS-CoV-2 titers|Rate of SARS-CoV-2 PCR Positivity|Duration of SARS-CoV-2 PCR Positivity|Levels of SARS-CoV-2 RNA
|
NCT04764747
|
Effectiveness of Convalescent Plasma in Hospitalized Patients With COVID-19 |
Completed |
|
Nov/01/2020 |
Apr/25/2021 |
- Alternative id - CP in COVID-19 patients
- Interventions -
- Study type - Observational
- Study results - No Results Available
- Locations - Al-Amal Hospital, Najaf, Iraq|Al-Hakeem Hospital, Najaf, Iraq
- Study designs - Observational Model: Cohort|Time Perspective: Retrospective
- Enrollment - 400
- Age - 18 Years to 95 Years (Adult, Older Adult)
- Outcome measures - Time to clinical improvement|Find the prediction factors associated with good outcome of patients on CP therapy|Time to negative PCR|Mortality rate|Hospital stay time|Adverse effect of plasma therapy
|
NCT04476888
|
Convalescent Plasma Treatment in COVID-19 |
Completed |
Not Applicable |
Apr/26/2020 |
Oct/10/2020 |
- Alternative id - CON000000000880
- Interventions - Biological: Convalescent Plasma (CP)|Other: Drugs and supportive care
- Study type - Interventional
- Study results - No Results Available
- Locations - Aga Khan University Hospital, Karachi, Sind, Pakistan
- Study designs - Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 110
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Decrease length of stay|Overall mortality|Incidence of adverse events related to Convalescent Plasma transfusion|Ordinal scale|Improvement in Laboratory Parameters: Serum Ferritin|Improvement in Laboratory Parameters: Procalcitonin|Improvement in Laboratory Parameters: C-Reactive Protein|Improvement in Laboratory Parameters: D-Dimer|Improvement in Laboratory Parameters: Complete Blood count|Chest X-Ray findings
|
NCT04346446
|
Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients |
Completed |
Phase 2 |
Apr/20/2020 |
May/30/2020 |
- Alternative id - ILBS-COVID-02
- Interventions - Drug: Convalescent Plasma Transfusion|Other: Supportive Care|Drug: Random Donor Plasma
- Study type - Interventional
- Study results - No Results Available
- Locations - Maulana Azad medical College, New Delhi, Delhi, India|Institute of Liver and Biliary Sciences, New Delhi, Delhi, India
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 29
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Proportion of patients remaining free of mechanical ventilation in both groups|Mortality in both groups|Improvement in Pa02/Fi02 ratio in both groups|Improvement in SOFA score in both groups|Duration of hospital Stay in both group.|Duration of Intensive Care Unit stay in both groups.|Requirements of Vasopressor in both groups.|Days free of dialysis in both groups.
|
NCT04803370
|
Efficacy of Reinforcing Standard Therapy in COVID-19 Patients With Repeated Transfusion of Convalescent Plasma |
Recruiting |
Not Applicable |
Jul/08/2020 |
Sep/01/2021 |
- Alternative id - CO-PLASMA-2020
- Interventions - Other: Convalescent Plasma with antibody against SARS-CoV-2.|Other: Standard treatment for COVID-19
- Study type - Interventional
- Study results - No Results Available
- Locations - University Hospital Son Llatzer, Palma De Mallorca, Islas De Balears, Spain
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 100
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - WHO clinical progression scale|lung X-ray|Concomitant medication assessment|Hematimetry|Activated partial thromboplastin time|Fibrinogen level|Fragment D-dimer assessment|Glomerular Filtration Rate assessment|Ferritin blood assessment|C-reactive protein assessment|Lactate Dehydrogenase (LDH) assessment|Troponin I assessment|Procalcitonin assessment|Interleukin-6 assessment|partial pressure of oxygen (pO2) assessment|Quantitative determination of antibodies|SARS-Cov-2 viral quantification in a nasopharyngeal specimen|Time to negativization of RT-PCR|Pneumonia Severity Index (PSI) score|Percentage of patients requiring admission to intensive care units.|Mortality rate at 15 days|Mortality rate at 30 days|Length of stay
|
NCT04669990
|
Remdesivir and Convalescent Plasma Therapy for Treatment of COVID-19 Infection in Nepal : A Registry Study |
Recruiting |
|
Nov/19/2020 |
Nov/19/2021 |
- Alternative id - 749-2020
- Interventions - Drug: Remdesivir
- Study type - Observational
- Study results - No Results Available
- Locations - Narayani Hospital, Birgunj, Nepal|Seti Provincial Hospital, Dhangadi, Nepal|BP Koirala Institute of Health Sciences (BPKIHS), Dharān Bāzār, Nepal|Bheri Provincial Hospital, Nepalgunj, Nepal
- Study designs - Observational Model: Case-Only|Time Perspective: Prospective
- Enrollment - 2000
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Demographics of recipients|Co-morbidity of recipient|Adverse events of convalescent COVID-19 plasma and Remdesivir Therapy|Hospital and ICU length of stay|Disposition of patients including survival
|
NCT04405310
|
Convalescent Plasma of Covid-19 to Treat SARS-COV-2 a Randomized Doble Blind 2 Center Trial |
Completed |
Phase 2 |
May/20/2020 |
Dec/10/2020 |
- Alternative id - DI/20/201/04/19
- Interventions - Biological: Convalescent Plasma of patients with COVID-19|Other: placebo (hartmann plus albumine)
- Study type - Interventional
- Study results - No Results Available
- Locations - Hospital Nava de Alta Especialidad, Mexico City, Mexico|Hospital General de Mexico Dr Eduardo Liceaga, Mexico City, Mexico
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment
- Enrollment - 42
- Age - 18 Years to 70 Years (Adult, Older Adult)
- Outcome measures - Death|Lenth of stay ICU|Days of Mechanical Ventilation|Suplemental Oxigen support|Viral Load by RT-PCR|Inflamatory biomarkers|SOFA (sequencial Organ Failure Assesment)
|
NCT04873414
|
Convalescent Plasma as Adjunct Therapy for COVID-19 |
Recruiting |
Phase 2|Phase 3 |
Dec/01/2020 |
Dec/31/2021 |
- Alternative id - COVID-CT002
- Interventions - Biological: Convalescent plasma treatment
- Study type - Interventional
- Study results - No Results Available
- Locations - Aceh Tamiang Hospital, Aceh Tamiang, Aceh, Indonesia|Sanglah Central Hospital, Denpasar, Bali, Indonesia|Udayana University Hospital, Denpasar, Bali, Indonesia|Dr. Soeradji Tirtonegoro Hospital, Klaten, Central Java, Indonesia|Dr. Wongsonegoro Regency Hospital, Semarang, Central Java, Indonesia|Pasar Minggu Hospital, Jakarta, DKI, Indonesia|Dr. Haryoto Regency Hospital, Lumajang, East Java, Indonesia|Waluyo Jati Kraksaan Regency Hospital, Probolinggo, East Java, Indonesia|Sidoarjo Regency Hospital, Sidoarjo, East Java, Indonesia|Dr Ramelan Navy Hospital, Surabaya, East Java, Indonesia|Dr. Soetomo Hospital, Surabaya, East Java, Indonesia|Emergency Hospital for COVID-19 - Wisma Atlet Kemayoran, Jakarta Pusat, Jakarta, Indonesia|Prof. Dr. R.D. Kandou Hospital, Manado, North Sulawesi, Indonesia|Dr. Tadjuddin Chalid Hospital, Makassar, Souh Sulawesi, Indonesia|Dr. Wahidin Sudirohusodo Central Hospital, Makassar, South Sulawesi, Indonesia|Hasanuddin University Hospital, Makassar, South Sulawesi, Indonesia|Dadi Hospital, Makassar, South Sulawesi, Indonesia|Dr. Mohammad Hoesin Central Hospital, Palembang, South Sumatra, Indonesia|Dr. Hasan Sadikin Central Hospital, Bandung, West Java, Indonesia|RSD Gunung Jati, Cirebon, West Java, Indonesia|Gatot Soebroto Central Army Hospital, Jakarta Pusat, Indonesia|dr. Cipto Mangunkusumo National Central General Hospital, Jakarta, Indonesia|YARSI Hospital, Jakarta, Indonesia|Dr. Suyoto Pusrehab Kemenhan Hospital, Jakarta, Indonesia|Persahabatan Central hospital, Jakarta, Indonesia|Fatmawati Central Hospital, Jakarta, Indonesia|Prof. Dr. Sulianti Saroso Infectious Disease Hospital, Jakarta, Indonesia|University Of Indonesia Hospital (RSUI), Jakarta, Indonesia
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 364
- Age - 18 Years to 60 Years (Adult)
- Outcome measures - The mortality in COVID-19 patients treated with convalescent plasma|Change in clinical status category in CP-receiving patients|Duration of hospitalization|Duration of mechanical ventilation|Duration of ICU stay|Change in lung image radiography in CP-receiving patients|Change in inflammatory parameters in CP-receiving patients|Change in coagulation parameters in CP-receiving patients|Change in viral load in CP-receiving patients|Changes in anti-SARS-CoV-2 antibody levels in CP-receiving patients|Systemic organ involvement in patients receiving CP treatment|Time to resolution of symptoms in patients receiving CP treatment|Treatment-related adverse events (AEs) and serious adverse events (SAEs)|Impact of anti-SARS-CoV-2 antibody levels in donors on the efficacy of CP therapy in CP-receiving patients|Impact of anti-SARS-CoV-2 antibody levels in donors on the viral clearance in CP-receiving patients
|
NCT04388527
|
COVID-19 Convalescent Plasma for Mechanically Ventilated Population |
Completed |
Phase 1 |
Apr/30/2020 |
Jan/30/2021 |
- Alternative id - 842996 (PennCCP-01)
- Interventions - Biological: COVID-19 Convalescent Plasma
- Study type - Interventional
- Study results - No Results Available
- Locations - Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
- Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 32
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Participants with serious adverse events.|Time to clinical improvement.|Clinical status assessment, using 8-point ordinal scale, of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Clinical status assessment using the National Early Warning Score (NEWS) of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Incidence of new oxygenation use up to Day 29 of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Duration of new oxygen use up to Day 29 of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Oxygen-free days of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Non-invasive ventilation/high flow oxygen days up to Day 29 of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Incidence of non-invasive ventilation/high flow oxygen up to Day 29 of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Duration of non-invasive ventilation/high flow oxygen up to Day 29 of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Ventilator/ECMO free days to Day 29 of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Incidence of new mechanical ventilation or ECMO use of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Duration of new mechanical ventilation or ECMO use of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006.|Duration of hospitalization of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006|Mortality of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006|Cumulative incidence of SAEs through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006.|Cumulative incidence of Grade 3 and Grade 4 clinical and/or laboratory adverse events through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006.|Changes in WBC with differential through day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006.|Changes in hemoglobin measurement through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006.|Changes in platelets measurement through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006..|Changes in creatinine measurement through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006..|Changes in glucose measurement through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006.|Changes in bilirubin measurement through Day 29 of convalescent plasma administration as compared to matched participants form the control arm of DMID Protocol No. 20-0006..|Changes in ALT measurement laboratory adverse events through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006.|Changes in AST measurement through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006.|Changes in PT measurement laboratory adverse events through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006.
|
NCT04716556
|
TranSfUsion of coNvalescent plAsma for the Early Treatment of pneuMonIa in COVID-19 Patients |
Completed |
Not Applicable |
Jul/16/2020 |
May/31/2021 |
- Alternative id - TSUNAMI
- Interventions - Biological: Convalescent plasma
- Study type - Interventional
- Study results - No Results Available
- Locations - SOD Clinica Malattie Infettive Tropicali, Parassitologia, Epatiti Croniche - AOU Ospedali Riuniti di Ancona, Ancona, Italy|Ospedale di Arezzo, Arezzo, Italy|Clinica Malattie Infettive, Università degli Studi di Bari, Bari, Italy|Ospedale Papa Giovanni XXIII-Dip. emergenza, Urgenza e area critica, Bergamo, Italy|UOC Malattie Infettive - AOU Bologna, Bologna, Italy|UO PID Tossicologia Applicata - Dip. Scienze Biomediche e Biotecnologiche - Università di Catania - AOU Policlinico Vittorio Emanuele, Catania, Italy|Ospedale Città di Castello, Città Di Castello, Italy|Ospedale di Empoli, Empoli, Italy|UOC Malattie Infettive - ASUR Marche Area Vasta 4, Fermo, Italy|UOC Malattie Infettive - AOU Ferrara, Ferrara, Italy|Ospedale Santa Maria Annunziata, Firenze, Italy|SOD Malattie Infettive e Tropicali - AOU Careggi, Firenze, Italy|Dip.Medicina Clinica e Sperimentale - Policlinico "Riuniti" di Foggia, Foggia, Italy|Nuovo Ospedale S. Giovanni Battista Usl Umbria2, Foligno, Italy|U.O.C. Malattie Infettive ASL Frosinone, Frosinone, Italy|U.O. Malattie Infettive IRCCS-Ospedale Policlinico San Martino, Genova, Italy|Ospedale di Grosseto, Grosseto, Italy|ASL 5 Spezzina - SC Malattie Infettive, La Spezia, Italy|ASST Lecco - Malattie Infettive, Lecco, Italy|Ospedale di Livorno, Livorno, Italy|Ospedale di Lucca, Lucca, Italy|S.C. Pneumologia e Utir ASST Mantova - Ospedale Carlo Poma, Mantova, Italy|Ospedale Dell'Angelo - UOC Malattie Infettive, Mestre, Italy|ASST Santi Paolo e Carlo, Milano, Italy|Ospedale Luigi Sacco, Milano, Italy|SC Malattie Infettive ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy|Ospedale San Gerardo, Monza, Italy|Malattie Infettive - AOU Federico II di Napoli, Napoli, Italy|UOC Malattie Infettive ad indirizzo Respiratorio - PO Cotugno - AORN "Dei Colli", Napoli, Italy|UOC Malattie Infettive e Tropicali - AOU Policlinico, Palermo, Italy|Dip. Medicina Diagnost. e Servizi Fondazione IRCCS Policlinico San Matteo, Pavia, Italy|Azienda Ospedaliero-Universitaria di Perugia, Perugia, Italy|UOC Malattie Infettive - Azienda Ospedali Riuniti Marche Nord, Pesaro, Italy|AOU Pisana, Pisa, Italy|Ospedale Pistoia, Pistoia, Italy|Ospedale Prato, Prato, Italy|Malattie Infettive Ravenna, Ravenna, Italy|UOC Malattie Infettive - AUSL Reggio Emilia, Reggio Emilia, Italy|Malattie Infettive - Rimini Forlì Cesena, Rimini, Italy|Campus Bio Medico - UO Anestesia e Rianimazione, Roma, Italy|ASL 1 Imperiese - SC Malattie Infettive, Sanremo, Italy|ASL 2 Savonese - SC Malattie Infettive, Savona, Italy|Ospedale di Siena, Siena, Italy|Ospedale di Sondrio - dipartimento di Medicina, Sondrio, Italy|AOU di Terni, Terni, Italy|Ospedale Ca Foncello - UOC Malattie Infettive, Treviso, Italy|A.O. Integrata Università di Verona, Verona, Italy|Ospedale Viareggio, Viareggio, Italy
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 474
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Number of patients who meet invasive mechanical ventilation or death|Mortality rates|Time to invasive mechanical ventilation or death|Time to virologic recover|Hospitalization time|Adverse events
|
NCT04376034
|
Convalescent Plasma Collection and Treatment in Pediatrics and Adults |
Recruiting |
Phase 3 |
Apr/16/2020 |
Mar/30/2021 |
- Alternative id - 2004965705
- Interventions - Biological: Convalescent Plasma 1 Unit|Biological: Convalescent Plasma 2 Units|Other: Standard of Care
- Study type - Interventional
- Study results - No Results Available
- Locations - WVU Medicine, Morgantown, West Virginia, United States
- Study designs - Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 240
- Age - 31 Days and older (Child, Adult, Older Adult)
- Outcome measures - Plasma Donor|Plasma Recipient
|
NCT04589949
|
Early Convalescent Plasma Therapy for High-risk Patients With COVID-19 in Primary Care (the CoV-Early Study) |
Recruiting |
Phase 3 |
Oct/12/2020 |
Nov/01/2023 |
- Alternative id - NL74972.078.20
- Interventions - Biological: ConvP|Biological: FFP
- Study type - Interventional
- Study results - No Results Available
- Locations - Erasmus Medical Center, Rotterdam, Zuid-Holland, Netherlands|Meander Medisch Centrum, Amersfoort, Netherlands|Rijnstate Ziekenhuis, Arnhem, Netherlands|Amphia Ziekenhuis, Breda, Netherlands|Groene Hart Ziekenhuis, Gouda, Netherlands|University Medical Center Groningen (UMCG), Groningen, Netherlands|Spaarne Gasthuis, Haarlem, Netherlands|Medisch Centrum Leeuwarden, Leeuwarden, Netherlands|Leids Universitair Medisch Centrum, Leiden, Netherlands|Sint Antonius Ziekenhuis, Nieuwegein, Netherlands|Bernhoven Hospital, Uden, Netherlands
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
- Enrollment - 690
- Age - 50 Years and older (Adult, Older Adult)
- Outcome measures - Highest disease status|Percentage of deaths|Percentage of hospital admissions|Percentage of ICU admissions|Disease duration in days of symptoms|Age and clinical frailty score
|
NCT04547660
|
Convalescent Plasma for Severe COVID-19 Patients |
Completed |
Phase 3 |
Jul/16/2020 |
Jan/07/2021 |
- Alternative id - 2020-0158
- Interventions - Biological: Convalescent Plasma|Other: Best Supportive Care
- Study type - Interventional
- Study results - No Results Available
- Locations - Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment
- Enrollment - 160
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Clinical improvement|6-point ordinal scale proportion at 14 days|6-point ordinal scale proportion at 28 days|Overall mortality|Days alive and free of respiratory support (DAFOR28)|Mechanical ventilation|PaO2/FiO2 ratio|Hospital stay|Lactate Dehydrogenase|Troponin I|C Reactive Protein|D-Dimers|Fibrinogen|Prothrombin Time (PT)|Activated Partial Thromboplastin Time (APTT)|Tumor Necrosis Factor Alfa (TNF-Alfa)|Interleukin-6 (IL-6)|RT-PCR|Sequential Organ Failure Assessment (SOFA) score|National Early Warning Score 2 (NEWS) 2|Safety and Adverse Events
|
NCT04467151
|
Administration of Anti-SARS-CoV-2 Convalescent Plasma in Hospitalized, Non-ICU Patients With COVID-19 |
Withdrawn |
Phase 2 |
Oct/01/2020 |
Dec/01/2021 |
- Alternative id - HS-20-00516
- Interventions - Drug: anti-SARS-CoV-2 plasma|Other: Placebo
- Study type - Interventional
- Study results - No Results Available
- Locations -
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
- Enrollment - 0
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Disease progression measured by WHO scale|Comparison of maximum WHO score per group|Comparison of decrease of median and maximum WHO score per group|Comparison of time to clinical improvement per group|Comparison of time to reach score of "6" or greater on the WHO scale
|
NCT04432103
|
Treatment of Severe and Critical COVID-19 Pneumonia With Convalescent Plasma |
Terminated |
Phase 3 |
Aug/08/2020 |
Jan/29/2021 |
- Alternative id - ABC-20-14
- Interventions - Biological: Anti SARS-CoV 2 Convalescent Plasma in severe COVID-19 patients|Biological: Anti SARS-CoV 2 Convalescent Plasma in critical COVID-19 patients
- Study type - Interventional
- Study results - No Results Available
- Locations - Centro Medico Abc, Mexico City, Mexico
- Study designs - Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 6
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - INCIDENCE OF CRITICAL PNEUMONIA|MORTALITY RATE AMONG CRITICAL PNEUMONIA PATIENTS|INCIDENCE OF MECHANICAL VENTILATION|DAYS OF MECHANICAL VENTILATION
|
NCT04375098
|
Efficacy and Safety of Early COVID-19 Convalescent Plasma in Patients Admitted for COVID-19 Infection |
Completed |
Phase 2 |
May/04/2020 |
Aug/17/2020 |
- Alternative id - 200415015
- Interventions - Biological: COVID-19 convalescent plasma
- Study type - Interventional
- Study results - No Results Available
- Locations - Hospital Clínico Universidad Católica, Santiago, Chile
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 58
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Percentage Mechanical Ventilation, hospitalization longer than 14 days or death during hospitalization|Median duration of fever|Median duration of mechanical ventilation|Median length of ICU stay|Median length of admission|Hospital mortality rate (percentage)|30-day mortality (percentage)|Readmission rate (percentage)|Median length of viral clearance
|
NCT04374487
|
Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications |
Active, not recruiting |
Phase 2 |
May/09/2020 |
Aug/09/2021 |
- Alternative id - MHC-COVID-19-CP
- Interventions - Drug: Convalescent Plasma|Other: Standard Care Therapy
- Study type - Interventional
- Study results - No Results Available
- Locations - Max Super Speciality hospital, Saket (A unit of Devki Devi Foundation), New Delhi, Delhi, India
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 100
- Age - 18 Years to 85 Years (Adult, Older Adult)
- Outcome measures - The primary outcome is a composite measure of the avoidance of - 1. Progression to severe ARDS (P/F ratio 100) and 2. All-cause Mortality at 28 days|Time to symptom resolution-Fever,Shortness of Breath,Fatigue|Hospital length of stay|Change in SOFA pre and post transfusion|Duration of respiratory support required a. Duration of Invasive Mechanical Ventilation b. Duration of Non-Invasive|Radiological improvement|Adverse events (AE) associated with transfusion|To measure the change in RNA levels (Ct values) of SARS-CoV-2 from RT-PCR [Time Frame: Days 0, 1, 3, and 7 after transfusion]|Levels of bio-markers pre and post transfusion|Need of Vasopressor use
|
NCT04452812
|
Statistical and Epidemiological Study Based on the Use of Convalescent Plasma for the Management of Patients With COVID-19 |
Not yet recruiting |
Phase 1|Phase 2 |
Jul/06/2020 |
Apr/01/2021 |
- Alternative id - HUS-001/2020
- Interventions - Biological: Convalescent plasma
- Study type - Interventional
- Study results - No Results Available
- Locations - Hospital Universitario "Dr. Gonzalo Valdés Valdés", Saltillo, Coahuila, Mexico
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment
- Enrollment - 15
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - All-cause mortality|Side effects|Length of stay in Intensive Care Unit (ICU)|Length of stay in hospitalization|Days of mechanical ventilation|Inflammatory biomarkers (d-dimer)|Inflammatory biomarkers (c-reactive protein)|Inflammatory biomarkers (lactate dehydrogenase)|Inflammatory biomarkers (ferritin)
|
NCT04356534
|
Convalescent Plasma Trial in COVID -19 Patients |
Completed |
Not Applicable |
Apr/19/2020 |
Jul/09/2020 |
- Alternative id - BDF/R&REC/2020-423
- Interventions - Other: plasma therapy using convalescent plasma with antibody against SARS-CoV-2|Other: Routine care for COVID-19 patients
- Study type - Interventional
- Study results - No Results Available
- Locations - Royal College of Surgeons in Ireland - Bahrain, Manama, Bahrain
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 40
- Age - 21 Years and older (Adult, Older Adult)
- Outcome measures - Requirement for invasive ventilation|Change in viral clearance|Radiological change|Change in white cell count|C reactive protein measurement|lactate dehydrogenase measurement|Procalcitonin measurement|D Dimer measurement|Ferritin measurement|Troponin T measurement|Brain naturetic peptide measurement|Mortality rate
|
NCT04332835
|
Convalescent Plasma for Patients With COVID-19: A Randomized, Single Blinded, Parallel, Controlled Clinical Study |
Completed |
Phase 2|Phase 3 |
Aug/08/2020 |
Nov/15/2020 |
- Alternative id - ABN011-2
- Interventions - Drug: Plasma|Drug: Standard Therapy
- Study type - Interventional
- Study results - No Results Available
- Locations - Universidad del Rosario, Bogota, Cundinamarca, Colombia
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment
- Enrollment - 92
- Age - 18 Years to 100 Years (Adult, Older Adult)
- Outcome measures - Change in Viral Load|Change in Immunoglobulin G COVID-19 Titers|Intensive Care Unit Admission|Length of Intensive Care Unit stay|Length of hospital stay (days)|Requirement of mechanical ventilation|Duration (days) of mechanical ventilation|Clinical status assessed according to the World Health Organization guideline|Mortality
|
NCT04338360
|
Expanded Access to Convalescent Plasma for the Treatment of Patients With COVID-19 |
Approved for marketing |
|
Jan/01/1970 |
Jan/01/1970 |
- Alternative id - 20-003312
- Interventions - Biological: COVID-19 convalescent plasma
- Study type - Expanded Access:Intermediate-size Population
- Study results - No Results Available
- Locations - Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Mayo Clinic Health System in Albert Lea, Albert Lea, Minnesota, United States|Mayo Clinic Health System in Austin, Austin, Minnesota, United States|Mayo Clinic Health System in Cannon Falls, Cannon Falls, Minnesota, United States|Mayo Clinic Health System in Lake City, Lake City, Minnesota, United States|Mayo Clinic Health System in Mankato, Mankato, Minnesota, United States|Mayo Clinic Health System in Owatonna, Owatonna, Minnesota, United States|Mayo Clinic Health System in Red Wing, Red Wing, Minnesota, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States|Mayo Clinic Health System - Eau Claire, Eau Claire, Wisconsin, United States|Mayo Clinic Health System - Franciscan Healthcare, La Crosse, Wisconsin, United States
- Study designs -
- Enrollment -
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures -
|
NCT04364737
|
CONTAIN COVID-19: Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients |
Active, not recruiting |
Phase 2 |
Apr/17/2020 |
Dec/31/2022 |
- Alternative id - 20-00541
- Interventions - Biological: Convalescent Plasma|Other: Saline solution
- Study type - Interventional
- Study results - No Results Available
- Locations - Yale University School of Medicine, New Haven, Connecticut, United States|University of Miami Hospital and Clinics, Miami, Florida, United States|Montefiore Medical Center, Bronx, New York, United States|NYU Langone Health, New York, New York, United States|University of Texas Rio Grande Valley, Edinburg, Texas, United States|The University of Texas Health Science Center, Houston, Texas, United States|The University of Texas Health Science Center, Tyler, Texas, United States|Aurora St. Luke's Medical Center, Milwaukee, Wisconsin, United States|Medical College of Wisconsin / Froedtert Memorial Lutheran Hospital, Milwaukee, Wisconsin, United States
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
- Enrollment - 384
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Score on the WHO 11-point ordinal scale for clinical improvement at 14 days|Score on the WHO 11-point ordinal scale for clinical improvement at 28 days
|
NCT04428021
|
Standard or Convalescent Plasma in Patients With Recent Onset of COVID-19 Respiratory Failure |
Completed |
Phase 2 |
Jun/15/2020 |
Oct/31/2021 |
- Alternative id - CS3/33
- Interventions - Drug: Standard Therapy Protocol (STP)|Other: STP + Standard Plasma (SP)|Other: STP + COVID-19 Convalescent Plasma (CP)
- Study type - Interventional
- Study results - No Results Available
- Locations - AO Città della salute e della scienza di Torino, Torino, Italy
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment
- Enrollment - 180
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - 30-days survival|Ventilator free survival|6-months survival|Incidence of complications|Days in intensive care units (ICU)|Positivity for Immunoglobulin G to SARS-Cov-2|Clearance of viral load|Sequential Organ Failure Assessment (SOFA) score|Any variation from Standard Therapy Protocol
|
NCT04642014
|
Application of Convalescent Plasma in the Treatment of SARS CoV-2 Disease (COVID-19) With Evaluation of Therapy Effectiveness |
Not yet recruiting |
Not Applicable |
Dec/01/2020 |
May/01/2022 |
- Alternative id - 2020.ABM.COVID19.0005
- Interventions - Biological: COVID-19 convalescent plasma treatment
- Study type - Interventional
- Study results - No Results Available
- Locations - Wroclaw Medical University, Wroclaw, Dolnośląskie, Poland
- Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 500
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Death, for any reason|For patients with respiratory support, the time to take one's own breath (extubation)|Stay in the intensive care unit (ICU)|Time to disconnect CPAP respiratory support|Time to elimination of SARS-Cov-2 (RT-PCR)|Time to serological response (anti-SARS-COv-2 antibodies)
|
NCT05046652
|
Effectiveness of Convalescent Plasma Therapy in 8 Non-Intubated COVID-19 Patients in Indonesia: A Case Series |
Completed |
|
Apr/01/2020 |
Dec/31/2020 |
- Alternative id - 0408087106
- Interventions - Biological: Convalescent Plasma Therapy
- Study type - Observational
- Study results - No Results Available
- Locations - Theresia Monica Monica, Bandung, West Java, Indonesia
- Study designs - Observational Model: Case-Only|Time Perspective: Retrospective
- Enrollment - 8
- Age - Child, Adult, Older Adult
- Outcome measures - Patients with two doses of CP tended to have faster recovery than those with one dose of CP.|Patients with two doses of CP tended to have faster PCR negative conversion time than those with one dose of CP
|
NCT04479163
|
Prevention of Severe Covid-19 in Infected Elderly by Early Administration of Convalescent Plasma With High-titers of Antibody Against SARS-CoV2 |
Completed |
Not Applicable |
Jun/04/2020 |
Oct/25/2020 |
- Alternative id - FundacionINFANT-Plasma
- Interventions - Biological: Convalescent Plasma|Other: Placebo
- Study type - Interventional
- Study results - No Results Available
- Locations - Hospital Militar Central, Caba, Buenos Aires, Argentina|CEMIC, Caba, Buenos Aires, Argentina|Centro de Investigacion Clinica OSECAC, Caba, Buenos Aires, Argentina|Centro Gallego de Buenos Aires, Caba, Buenos Aires, Argentina|Sanatorio Anchorena, Caba, Buenos Aires, Argentina|Sanatorio de Los Arcos, Caba, Buenos Aires, Argentina|Hospital "Simplemente Evita", González Catán, Buenos Aires, Argentina|Hospital Especializado de Agudos y Crónicos "San Juan de Dios", La Plata, Buenos Aires, Argentina|Clinica Olivos, Buenos Aires, Argentina|Hospital Central de San Isidro, Buenos Aires, Argentina|Hospital General de Agudos "Dr. Carlos Bocalandro", Buenos Aires, Argentina
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
- Enrollment - 165
- Age - 65 Years and older (Older Adult)
- Outcome measures - Development of severe respiratory disease defined as a respiratory rate (RR)>30 and/or an O2 sat<93%|Life threatening respiratory disease|Critical systemic illness, defined as respiratory failure|Death|Combination of secondary outcomes #2 (Life threatening respiratory disease) and/or #3 (Critical systemic illness, defined as respiratory failure) and//or #4 (death)|Duration of oxygen support requirement in patients with covid-19 due to saturation in ambient air <93%.
|
NCT05247307
|
Efficacy of the Infusion of Donor Plasma in COVID-19 Infection |
Terminated |
Phase 3 |
Mar/31/2020 |
Dec/31/2021 |
- Alternative id - SARS VOC 2 GALDAKAO 02
- Interventions - Biological: convalescent plasma infusion covid 19
- Study type - Interventional
- Study results - No Results Available
- Locations - Hospital Galdakao-Usansolo, Galdakao, Bizkaia, Spain
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
- Enrollment - 93
- Age - 65 Years and older (Older Adult)
- Outcome measures - Rate of hospital admission|Rate of severity of the disease|Rate of of deaths|Rate of complications
|
NCT04558476
|
Efficacy of CONvalescent Plasma in Patients With COVID-19 Treated With Mechanical Ventilation |
Recruiting |
Phase 2 |
Sep/01/2020 |
Sep/01/2022 |
- Alternative id - 2020-003102-31
- Interventions - Biological: Convalescent Plasma|Other: Standard of Care
- Study type - Interventional
- Study results - No Results Available
- Locations - Clinique Saint Pierre Ottignies, Ottignies, Brabant Wallon, Belgium|Centre Hospitalier Wallonie Picarde, Tournai, Hainaut, Belgium|OLVZ Aalst, Aalst, Belgium|UZ Antwerpen, Antwerp, Belgium|Imelda ZH Bonheiden, Bonheiden, Belgium|AZ Sint-Jan Brugge, Bruges, Belgium|CHU Saint Pierre, Brussels, Belgium|Erasme, Brussels, Belgium|UZ Brussel, Brussel, Belgium|CHU Charleroi Marie Curie, Charleroi, Belgium|AZ Sint Blasius, Dendermonde, Belgium|UZ Gent, Gent, Belgium|AZ Groeningen Kortrijck, Kortrijk, Belgium|CHR Citadelle, Liège, Belgium|CHU Liège, Liège, Belgium|UC Louvain, Louvain, Belgium|AZ Delta, Roeselare, Belgium|CHU UCL Namur-Godinne, Yvoir, Belgium
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 500
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Vital status|day 90 mortality|number of ventilator-free days at day 28|number of renal replacement therapy free days at day 28|number of vasopressors free-days at day 28|use of ECMO before day 28|value of the SOFA score at days 7, 14 and 28|changes in SOFA scores (delta SOFA) over 7, 14 and 28 days|assessment of the SARS-CoV-2 viral load|blood C reactive protein (CRP) concentration|ferritin concentration|lymphocyte count|length of stay in the acute care hospital|location of the patient|Katz Index of independence in Activity Day Living functional score|Hospital Anxiety and Depression Scale (HADS)|Quality of life scale EQ-5D-5L|Transfusion related adverse events
|
NCT04397757
|
COVID-19 Convalescent Plasma for the Treatment of Hospitalized Patients With Pneumonia Caused by SARS-CoV-2. |
Completed |
Phase 1 |
May/13/2020 |
Mar/08/2021 |
- Alternative id - 843003 (PennCCP-02)
- Interventions - Biological: COVID-19 Convalescent Plasma
- Study type - Interventional
- Study results - No Results Available
- Locations - Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 80
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Participants with serious adverse events.|Comparison of clinical severity score between patients on the experimental versus control arms;|Clinical status assessment, using 8-point ordinal scale, of convalescent plasma administration by comparing treatment vs control arms|Clinical status assessment using the National Early Warning Score (NEWS) of convalescent plasma administration by comparing treatment vs control arms|Oxygen-free days of convalescent plasma administration by comparing treatment vs control arms|Incidence of new oxygenation use up to Day 29 of convalescent plasma administration by comparing treatment vs control arms|Duration of new oxygen use up to Day 29 of convalescent plasma administration by comparing treatment vs control arms|Non-invasive ventilation/high flow oxygen days up to Day 29 of convalescent plasma administration by comparing treatment vs control arms|Incidence of non-invasive ventilation/high flow oxygen up to Day 29 of convalescent plasma administration by comparing treatment vs control arms|Duration of non-invasive ventilation/high flow oxygen up to Day 29 of convalescent plasma administration by comparing treatment vs control arms|Ventilator/ECMO free days to Day 29 of convalescent plasma administration by comparing treatment vs control arms|Incidence of new mechanical ventilation or ECMO use of convalescent plasma administration by comparing treatment vs control arms|Duration of new mechanical ventilation or ECMO use of convalescent plasma administration by comparing treatment vs control arms|Duration of hospitalization of convalescent plasma administration by comparing treatment vs control arms|Mortality of convalescent plasma administration by comparing treatment vs control arms|Cumulative incidence of SAEs through Day 29 of convalescent plasma administration by comparing treatment vs control arms|Cumulative incidence of Grade 3 and Grade 4 clinical and/or laboratory adverse events through Day 29 of convalescent plasma administration by comparing treatment vs control arms|Changes in WBC with differential through day 29 of convalescent plasma administration by comparing treatment vs control arms|Changes in hemoglobin measurement through Day 29 of convalescent plasma administration by comparing treatment vs control arms|Changes in platelets measurement through Day 29 of convalescent plasma administration by comparing treatment vs control arms|Changes in creatinine measurement through Day 29 of convalescent plasma administration by comparing treatment vs control arms|Changes in glucose measurement through Day 29 of convalescent plasma administration by comparing treatment vs control arms|Changes in bilirubin measurement through Day 29 of convalescent plasma administration by comparing treatment vs control arms|Changes in ALT measurement laboratory adverse events through Day 29 of convalescent plasma administration by comparing treatment vs control arms|Changes in AST measurement through Day 29 of convalescent plasma administration by comparing treatment vs control arms|Changes in PT measurement laboratory adverse events through Day 29 of convalescent plasma administration by comparing treatment vs control arms
|
NCT04292340
|
Anti-SARS-CoV-2 Inactivated Convalescent Plasma in the Treatment of COVID-19 |
Unknown status |
|
Feb/01/2020 |
Dec/31/2020 |
- Alternative id - Anti-SARS-CoV-2
- Interventions -
- Study type - Observational
- Study results - No Results Available
- Locations - Shanghai Public Health Clinical Center, Shanghai, Shanghai, China
- Study designs - Observational Model: Case-Only|Time Perspective: Prospective
- Enrollment - 15
- Age - Child, Adult, Older Adult
- Outcome measures - The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 1|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 3|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7|Numbers of participants with different Clinical outcomes|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
|
NCT04869072
|
Convalescent Plasma Therapy - Zurich Protocol |
Completed |
Phase 1 |
Apr/29/2020 |
Mar/30/2021 |
- Alternative id - 2020-00787
- Interventions - Drug: Convalescent plasma
- Study type - Interventional
- Study results - No Results Available
- Locations - University Hospital Zurich, Zürich, Switzerland
- Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 30
- Age - Child, Adult, Older Adult
- Outcome measures - Safety of CPT applied to COVID-19 patients|Improvement of respiratory frequency|Improvement of O2-saturation|Improvement of Inflammatory markers (C Reactive Protein, CRP)|Improvement of Inflammatory markers (Ferritin)|Improvement of Inflammatory markers (IL-6)|Improvement of coagulation-markers (D-dimer)|Improvement of coagulation-markers (Fibrinogen)|Improvement of coagulation-markers (LDH)|Prevention of ICU-admission|Characterisation of virus reaction to plasma Therapy|Characterisation of the dynamic of humoral response after therapy|Better characterize the the in-vivo anti-virus humoral response against SARS-CoV-2.
|
NCT04384588
|
COVID19-Convalescent Plasma for Treating Patients With Active Symptomatic COVID 19 Infection (FALP-COVID) |
Recruiting |
Phase 2|Phase 3 |
Apr/07/2020 |
Apr/06/2021 |
- Alternative id - FALP 001-2020
- Interventions - Biological: Convalescent Plasma from COVID-19 donors
- Study type - Interventional
- Study results - No Results Available
- Locations - Fundacion Arturo Lopez Perez, Providencia, Santiago, Chile
- Study designs - Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 100
- Age - 15 Years and older (Child, Adult, Older Adult)
- Outcome measures - in-hospital mortality secondary to COVID-19 among patients treated with convalescent plasma|safety of the use of convalescent plasma drom COVID 19 donors|Mortality at 30 days, 90 days, 6 months and 1 year|in-hospital Mortality COVID-19 related compared with non-treated population according to Chilean official reports|Number of days of hospitalization in high complexity facilities after convalescent plasma use|Number of days of hospitalization in intensive care unit after convalescent plasma use|Number of days of mechanical ventilatory support in patients after convalescent plasma use|Total number of days of mechanical ventilatory support|Total number of hospitalization days in patients treated with convalescent plasma|Number of hospitalization days in patients after treatment with convalescent plasma|Viral load measuring|Immunological response in treated patients (COVID19-Immunoglobulin M and Immunoglobulin G, neutralizing antibodies)|Negativization of COVID 19 load since convalescent plasma use|Negativization of COVID 19 load since hospitalization|Negativization of COVID 19 load since first reported symptoms COVID-19 related|Donor Interferon Gamma profile characterization|Donor Granulocyte Macrophage Colony Stimulating Factor characterization|Donor Tumor Necrosis Factor Alfa characterization|Donor Interleukin -1 beta characterization|Donor Interleukin-2 characterization|Donor Interleukin-4 characterization|Donor Interleukin-6 characterization|Donor Interleukin-8 characterization|Donor Interleukin-10 characterization|Receptor Interferon Gamma profile characterization|Receptor Granulocyte Macrophage Colony Stimulating Factor characterization|receptor Tumor Necrosis Factor Alfa characterization|receptor Interleukin -1 beta characterization|Receptor Interleukin-2 characterization|Receptor Interleukin-4 characterization|Receptor Interleukin-6 characterization|Receptor Interleukin-8 characterization|Receptor Interleukin-10 characterization
|
NCT04681430
|
Reconvalescent Plasma/Camostat Mesylate Early in SARS-CoV-2 Q-PCR (COVID-19) Positive High-risk Individuals |
Completed |
Phase 2 |
Jan/08/2021 |
Oct/29/2021 |
- Alternative id - RES-Q-HR|2020-004695-18
- Interventions - Biological: Convalescent plasma|Drug: Camostat Mesilate|Drug: Placebo for Camostat Mesilate|Other: Standard of Care (SoC)
- Study type - Interventional
- Study results - No Results Available
- Locations - Abteilung Infektiologie Klinik für Innere Medizin II Department Innere Medizin Universitätsklinikum Freiburg, Freiburg im Breisgau, Baden-Württemberg, Germany|Klinik und Poliklinik für Innere Medizin II Klinikum rechts der Isar Technische Universität München, München, Bavaria, Germany|Universitätsklinikum Frankfurt Medizinische Klinik 2: Hämatologie, Onkologie, Hämostaseologie, Rheumatologie, Infektiologie/HIV, Frankfurt am Main, Hessen, Germany|Universitätsklinikum Düsseldorf Klinik für Hepatologie und Infektiologie, Duesseldorf, North Rhine Westphalia, Germany|Klinikum Dortmund, Dortmund, North Rhine-Westphalia, Germany|Universitätsklinikum Essen, Essen, North Rhine-Westphalia, Germany
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
- Enrollment - 22
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - WHO ordinal Covid-19 scale up to day 28|Cumulative number WHO categories 4b-8|Cumulative number WHO categories 3-4a|Not hospitalized|All-cause mortality|Reinfection|Secondary sclerosing cholangitis (SSC)|chronic pulmonary disease as sequelae from COVID-19|patients with remdesivir treatment|COVID-19 WHO status of patients at start of remdesivir treatment|patients with dexamethasone treatment|COVID-19 WHO status of patients at start of dexamethasone treatment|resolution of COVID-19 symptoms|negative SARS-CoV-2-PCR test|Oxygen therapy|COVID-19 pneumonia|Percentage of participants requiring mechanical ventilation|Number of ventilation days per participant up to day 90|hospital stay and intensive care|Mortality|SAEs|Grade 3/4 AEs|SARS-CoV-2 antibody IgA concentrations|SARS-CoV-2 antibody IgG concentrations|SARS-CoV-2 neutralizing antibody titers|Plasma treatment screening failures
|
NCT04327349
|
Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial |
Unknown status |
Not Applicable |
Mar/28/2020 |
Sep/30/2020 |
- Alternative id - IR.MAZUMS.REC.1399.7330|IRCT20181104041551N1
- Interventions - Biological: Convalescent Plasma
- Study type - Interventional
- Study results - No Results Available
- Locations - Imam Khomeini Hospital, Mazandaran University of Medical Sciences, Sari, Mazandaran, Iran, Islamic Republic of
- Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 30
- Age - 30 Years to 70 Years (Adult, Older Adult)
- Outcome measures - Mortality changes in day 10|Mortality changes in day 30|Changes of C-reactive protein|Changes of Interleukin 6|Changes of tumor necrosis factor-α|Changes of PaO2/FiO2 Ratio|Changes of CD3|Changes of CD4|Changes of CD8|Changes of CD4/CD8 ratio|Changes of lymphocyte count|Changes of leukocyte count|Changes of alanine transaminase (ALT)|Changes of aspartate transaminase (AST)|Changes of alkaline phosphatase (ALP)|Changes of lactate dehydrogenase (LDH)|Changes of creatine phosphokinase (CPK)|Changes of Creatine kinase-MB (CK-MB)|Changes of Specific IgG|Radiological findings|Number of days ventilated|Length of hospitalization
|
NCT04383535
|
Convalescent Plasma and Placebo for the Treatment of COVID-19 Severe Pneumonia |
Completed |
Not Applicable |
May/15/2020 |
Sep/27/2020 |
- Alternative id - 5565
- Interventions - Other: Convalescent SARS COVID-19 plasma|Other: Placebo
- Study type - Interventional
- Study results - No Results Available
- Locations - Hospital Italiano de Buenos Aires, Ciudad Autonoma de Buenos Aire, Ciudad Autonoma De Buenos Aires, Argentina
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
- Enrollment - 333
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Clinical status during follow-up at 30th day|Clinical status during follow-up at 7th day|Clinical status during follow-up at 14th day|Time until hospital discharge (days).|Time until discharge from ICU (days)|Time to death|Time until complete functional recovery|Percentage of participants with adverse events / serious adverse events|Percentage of patients with negative SARS-CoV-3 PCR at Day 14th|D Dimer plasma concentration at Day 14th|Ferritin plasma concentration at Day 13th|Plasma concentration of neutralizing antibodies at Day 2nd|Plasma concentration of neutralizing antibodies at Day 7th|Post-transfusion adverse reactions
|
NCT04433910
|
A Clinical Trial of Convalescent Plasma Compared to Best Supportive Care for Treatment of Patients With Severe COVID-19 |
Completed |
Phase 2 |
Aug/30/2020 |
Feb/22/2021 |
- Alternative id - CAPSID2020-DRK-BSD|2020-001310-38
- Interventions - Drug: Convalesscent Plasma
- Study type - Interventional
- Study results - No Results Available
- Locations - University Hospital Ulm, Ulm, Baden-Württmberg, Germany|University Hopsital Frankfurt, Frankfurt, Hessia, Germany|Saarland University Hospital, Homburg, Saarland, Germany|University Hospital Berlin, Charite, Berlin, Germany|Universitiy Hospital Dresden, Dresden, Germany|University Düsseldorf, Düsseldorf, Germany|University Hospital Freiburg, Freiburg, Germany|University Hospital Gießen, Gießen, Germany|University Hopsital Greifswald, Greifswald, Germany|Städtisches Klinikum Karslruhe, Karlsruhe, Germany|Universtity Hospital Schleswig-Holstein, Kiel, Germany|Universtity Hospital Schleswig-Holstein, Lübeck, Germany|University Hospital Mannheim, Mannheim, Germany|University Hospital Marburg, Marburg, Germany|Klinikum Stuttgart, Stuttgart, Germany|University Hospital Tübingen, Tübingen, Germany
- Study designs - Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 106
- Age - 18 Years to 75 Years (Adult, Older Adult)
- Outcome measures - Composite endpoint of survival and no longer fulfilling criteria of severe COVID-19.|Time to clinical improvement|Frequency and severity of adverse events by CTCAE v5.0, (Key secondary endpoint)|Case fatality rate|Length of hospital stay Length of hospital stay (if applicable)|Length of stay in ICU|Duration of ventilation support / ECMO|Time until negative SARS-CoV-2 PCR (nasopharyngeal sample)|Predictive value of comorbidities|Predictive value of coagulation markers|Predictive value of inflamation|Percentage of former COVID-19 patients willing to donate qualifying for plasma donation.|Amount of Plasma Units that could be collected for the clinical trial|Titer of anti-SARS-CoV-2 in transfused plasma units|Impact of donor characteristics on anti-SARS-CoV-2 humoral response|Course of anti-SARS-CoV-2 titer in both patient groups at different time points related to transfusion of convalescent plasma|Correlation of anti-SARS-CoV-2 titer in transfused plasma units and primary and key secondary outcomes.|Effect of timing of plasma transfusions
|
NCT04380935
|
Effectiveness and Safety of Convalescent Plasma Therapy on COVID-19 Patients With Acute Respiratory Distress Syndrome |
Recruiting |
Phase 2|Phase 3 |
May/18/2020 |
Oct/31/2020 |
- Alternative id - convalescent plasma RSCM-FKUI
- Interventions - Biological: Convalescent plasma|Drug: Standard of care
- Study type - Interventional
- Study results - No Results Available
- Locations - Dr. Cipto Mangunkusumo General Hospital, Jakarta, DKI Jakarta, Indonesia|St. Carolus Hospital, Jakarta, DKI Jakarta, Indonesia|Ciputra Hospital CitraRaya, Jakarta, DKI Jakarta, Indonesia
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 60
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - All-cause mortality|Length of stay in intensive care unit|Duration of mechanical ventilation|Body temperature (degree in Celsius)|The Sequential Organ Failure Assessment (SOFA) Score|PAO2/FIO2 ratio|C-Reactive Protein (CRP) in mg/L|D-Dimer in ng/mL|Procalcitonin in ng/mL|Interleukin 6 (IL-6) in pg/mL|Allergic/ anaphylaxis transfusion reaction|Hemolytic transfusion reaction|Transfusion Related Acute Lung Injury|Transfusion associated Circulatory Overload
|
NCT04392414
|
Hyperimmune Convalescent Plasma in Moderate and Severe COVID-19 Disease |
Completed |
Phase 2 |
May/01/2020 |
Sep/23/2020 |
- Alternative id - CovPlas-Covid19
- Interventions - Biological: COVID-19 convalescent hyperimmune plasma|Biological: Non-convalescent fresh frozen plasma (Standard plasma)
- Study type - Interventional
- Study results - No Results Available
- Locations - Federal Research Clinical Center of Federal Medical & Biological Agency, Moscow, Russian Federation
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 60
- Age - 18 Years to 75 Years (Adult, Older Adult)
- Outcome measures - The number and proportion of patients with the normal body temperature (≤37.2 C) at the day 1, 2, 3, 4, 5, 6, 7 after the start of therapy|Days before mechanical ventilation|Days of need for oxygen therapy|Days of stay in the ICU|Days of hospitalization|Changes of the titer of the SARS-CoV-2 antibodies in the blood plasma of patients|Dynamics of the cytokine profile|Incidence of the cytokine storm development and the need of administering cytokine storm inhibitors|Dynamics of the level of C-reactive protein|30-day mortality rate
|
NCT04468009
|
Treatment of Critically Ill Patients With Covid-19 With Convalescent Plasma |
Completed |
Phase 2 |
Jun/25/2020 |
Jun/19/2021 |
- Alternative id - 1725
- Interventions - Biological: Convalescent plasma
- Study type - Interventional
- Study results - No Results Available
- Locations - Hospital Francisco Javier Muñiz, Ciudad Autonoma de Buenos Aire, Argentina
- Study designs - Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 134
- Age - 18 Years to 100 Years (Adult, Older Adult)
- Outcome measures - Mortality at ICU at 30 days|Mortality at ICU at 90 days|SOFA score of study days 1, 3, 5, 7, 14 and 28|Need for supportive therapy after enrollment|Lenght of stay in ICU|Lenght of mechanical ventilation|Lenght of hospitalization
|
NCT04836260
|
Preemptive Use of Convalescent Plasma for High-risk Patients With COVID-19 |
Recruiting |
Phase 3 |
Apr/08/2021 |
Dec/31/2021 |
- Alternative id - 2020-02989
- Interventions - Drug: SARS-CoV-2 convalescent plasma
- Study type - Interventional
- Study results - No Results Available
- Locations - Universitätsspital Basel, Basel, Switzerland|HFR-Fribourg Hôpital Cantonal, Fribourg, Switzerland|Geneva University Hospitals, Geneva, Switzerland|Ospedale Regionale di Lugano, Lugano, Switzerland
- Study designs - Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention
- Enrollment - 100
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Proportion of patient that progress to WHO 8 ordinal scale ≥ 4 (oxygen requirement)|Proportion of death|Proportion of patients with cleared nasopharyngeal viral load
|
NCT04377568
|
Efficacy of Human Coronavirus-immune Convalescent Plasma for the Treatment of COVID-19 Disease in Hospitalized Children |
Withdrawn |
Phase 2 |
Oct/07/2020 |
May/01/2022 |
- Alternative id - 1000070143
- Interventions - Biological: Convalescent plasma (CP)
- Study type - Interventional
- Study results - No Results Available
- Locations - Alberta Children's Hospital, Calgary, Alberta, Canada|Stollery Children's Hospital, Edmonton, Alberta, Canada|BC Children's Hospital, Vancouver, British Columbia, Canada|Winnipeg Children's Hospital, Winnipeg, Manitoba, Canada|IWK Health Centre, Halifax, Nova Scotia, Canada|McMaster Children's Hospital, Hamilton, Ontario, Canada|Kingston Health Sciences Centre, Kingston, Ontario, Canada|Children's Hospital, London, Ontario, Canada|Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada|The Hospital for Sick Children, Toronto, Ontario, Canada|CHU Sainte-Justine, Montréal, Quebec, Canada|McGill Univ Health Ctr - Montreal Children's Hospital, Montréal, Quebec, Canada|Jim Pattison Children's Hospital, Saskatoon, Saskatchewan, Canada
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 0
- Age - up to 18 Years (Child, Adult)
- Outcome measures - Clinical recovery|Combined mortality/intubation|Respiratory status-1|Respiratory status-2|Respiratory status-3|respiratory status -4|respiratory status -5|respiratory status-6|Mortality 1a|Mortality 1b|Mortality 2a|Mortality 2b|Care and Critical Care|organ systems: renal|organ systems: cardiac|Transfusion-associated adverse events (AE)|Safety of the intervention|organ systems: multi-system inflammatory disease
|
NCT04429854
|
Donated Antibodies Working Against nCoV |
Completed |
Phase 2 |
May/02/2020 |
Apr/30/2021 |
- Alternative id - S63992
- Interventions - Biological: Convalescent Plasma|Drug: Standard of care
- Study type - Interventional
- Study results - No Results Available
- Locations - ZNA, Antwerpen, Belgium|Imelda Ziekenhuis Bonheiden, Bonheiden, Belgium|Institut Bordet, Brussel, Belgium|UMC Sint-Pieter, Brussel, Belgium|CHU Brugmann, Brussel, Belgium|Erasmus Ziekenhuis, Brussel, Belgium|UZ Brussel, Brussel, Belgium|Cliniques Universitaires St Luc, Brussel, Belgium|AZ Sint-Vincentius, Deinze, Belgium|AZ Maria Middelares, Gent, Belgium|AZ Sint-Lucas, Gent, Belgium|AZ Groeninge, Kortrijk, Belgium|UZ Leuven, Leuven, Belgium|CHC Liège Mont Légia, Liège, Belgium|CHR Citadelle Liège, Liège, Belgium|CHU Liège Sart-Tilman, Liège, Belgium|CHU Ambroise Paré, Mons, Belgium|CHR Jolimont Mons-Hainaut, Mons, Belgium|AZ Delta, Roeselare, Belgium|Sint-Trudo Ziekenhuis, Sint-Truiden, Belgium|Centre Hospitalier de Wallonie Picarde (CHwapi), Tournai, Belgium
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 483
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Patients requiring mechanical ventilation or death|Clinical status of subject at day 15 and day 30 (on a 10-point "WHO progression" ordinal scale)
|
NCT04516811
|
Therapeutic Use of Convalescent Plasma in the Treatment of Patients With Moderate to Severe COVID-19 |
Recruiting |
Phase 3 |
Sep/21/2020 |
Jul/31/2022 |
- Alternative id - PROTECT-Patient trial
- Interventions - Biological: COVID-19 convalescent plasma (CCP) plus standard of care (SOC)|Biological: Standard of care (SOC) plus placebo
- Study type - Interventional
- Study results - No Results Available
- Locations - Universitas Hospital, Bloemfontein, Free State, South Africa|Mitchells Plain Hospital, Cape Town, Western Cape, South Africa
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
- Enrollment - 600
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Clinical Improvement|Adverse Events of special interest|Serious Adverse Events|Survival|Invasive mechanical ventilation|Disease severity|Time to outcomes of interest|Length of stay meausures|SARS-CoV PCR|Inflammatory markers|Radiography|Fever & Hypoxia|patients with HIV infection and other comorbidities|Timing of IP & Efficacy Outcome|Neutralising Ab|SARS CoV Antibody titre
|
NCT04362176
|
Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults |
Completed |
Phase 3 |
Apr/24/2020 |
Aug/06/2021 |
- Alternative id - 200738|3UL1TR002243-04S3
- Interventions - Biological: pathogen reduced SARS-CoV-2 convalescent plasma|Biological: Placebo
- Study type - Interventional
- Study results - No Results Available
- Locations - University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Scripps Health, La Jolla, California, United States|University of Colorado Denver, Aurora, Colorado, United States|MedStar Health Research Institute/MedStar Washington Hospital Center, Washington, District of Columbia, United States|Cleveland Clinic Florida, Weston, Florida, United States|University of Chicago, Chicago, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|The University of Kansas Medical Center, Kansas City, Kansas, United States|Our Lady of the Lake Regional Medical Center, Baton Rouge, Louisiana, United States|University of Maryland, Baltimore (University of Maryland Medical Center), Baltimore, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Newton-Wellelsey Hospital, Newton, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States|University at Buffalo/Buffalo General Medical Center, Buffalo, New York, United States|Rochester General Hospital, Rochester, New York, United States|Cleveland Clinic Ohio, Cleveland, Ohio, United States|The Ohio State University Wexner Medical Center and James Cancer Hospital, Columbus, Ohio, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Meharry Medical College, Nashville, Tennessee, United States|Utah Valley Hospital, Provo, Utah, United States|University of Utah Health, Salt Lake City, Utah, United States|Sentara Norfolk General Hospital, Norfolk, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States|University of Washington, Seattle, Washington, United States
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment
- Enrollment - 974
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - COVID-19 7-point Ordinal Clinical Progression Outcomes Scale|All-location, all-cause 14-day mortality|All-location, all-cause 28-day mortality|Survival through 28 days|Time to hospital discharge through 28 days|COVID-19 7-point Ordinal Clinical Progression Outcomes Scale on Study Day 3|COVID-19 7-point Ordinal Clinical Progression Outcomes Scale on Study Day 8|COVID-19 7-point Ordinal Clinical Progression Outcomes Scale on Study Day 29|Oxygen-free days through Day 28|Ventilator-free days through Day 28|Vasopressor-free days through Day 28|ICU-free days through Day 28|Hospital-free days through Day 28
|